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ABSTRACT
ROLE OF HUMAN ARYLAMINE N-ACETYLTRANSFERASE 1 IN
TUMORIGENESIS AND CANCER BIOLOGY
Marcus W. Stepp
June 12th, 2017

Human arylamine N-acetyltransferase 1 (NAT1) is a well-known phase II
metabolic enzyme that has been associated with carcinogenesis. Its role in the
biotransformation of aromatic and heterocyclic amine carcinogens has been
investigated for many years, but more recent investigations focus on a possible
endogenous role of human NAT1 in cancer initiation and progression. To further
explore and understand possible endogenous roles for NAT1, we conducted in
vitro enzymatic reactions, in vivo studies using homozygous high (rapid) or low
(slow) NAT2 activity congenic F344.WKY rats, and genetically modified human
breast cancer cell lines. Human NAT1 and rodent NAT2 hydrolyzed acetylcoenzyme A (AcCoA) in a folate-dependent manner. This hydrolytic function of
human NAT1 also was measured with an endogenous folate compound
dihydrofolate. The rat Nat2 gene is a functional ortholog for the human NAT1
because it has similar sequence and substrate specificity to human NAT1. Rapid
acetylator NAT2 congenic rats developed more mammary tumors than the slow
acetylator NAT2 congenic rats following administration of the mammary
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carcinogens methylnitrosourea and 7,12-dimethylbenzanthracene, neither of
which is metabolized by rat NAT2. Investigations of partial NAT1 knockdown and
complete NAT1 knockout were completed in MDA-MB-231 and MCF7 human
breast cancer cell lines. Both partial and complete NAT1 knockout reduced ability
for colony formation in soft agar compared to parental cell lines. Endogenous
AcCoA levels in congenic rat embryonic fibroblasts and in human breast cancer
cell lines with partial and complete NAT1 knockout showed increased AcCoA
when the level of NAT1 was reduced within the cells. In summary, the findings
compliment but do not fully replicate previous reports regarding the effect of
reducing NAT1 activity on cancer cell properties. In our studies, partial
knockdown or complete removal of NAT1-catalyzed N-acetylation in the MDAMB-231 and MCF7 breast cancer cell line by CRISPR/Cas9 resulted in a
significant decrease in anchorage-independent colony formation without affecting
overall cell growth and relative invasion ability. NAT1 knockout cell lines had
increased endogenous AcCoA levels, about 45%, compared to the parental cell
line. The results warrant further studies to determine mechanisms to understand
how reduced NAT1 activity is related to reduced formation of anchorageindependent colonies. Use of this model system further suggests that human
NAT1 could serve as a target for the prevention and/or treatment of breast
cancer.
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CHAPTER I
INTRODUCTION
The

human

genome

codes

for

two

functional

arylamine

N-

acetyltransferases (NATs), NAT1 and NAT2, that are located on the short arm of
chromosome 8 [1]. Human NAT1 is expressed in nearly all human tissues [2, 3].
Human NAT2 is expressed primarily in the liver and gut [4]. The two NATs differ
from each other in substrate specificity, structural stability, and tissue specific
expression [5]. There is also an inactive NAT pseudogene known as NATP [6].
The NAT1 protein is a phase II cytosolic isoenzyme responsible for the
metabolism of arylamine xenobiotics, including such environmental and
occupational carcinogens like 4-aminobiphenyl (ABP)[7]. NAT1 catalyzes both Nacetylation and O-acetylation. The N-acetylation of aromatic and heterocyclic
amine xenobiotics results in the inactivation of compounds, and the inactivated
compound is removed by urinary excretion. After N-hydroxylation of aromatic and
heterocyclic amine xenobiotics by a cytochrome P450, O-acetylation catalyzed
by NAT1 produces an unstable highly reactive nitrenium ion. This nitrenium ion is
able to react with DNA forming DNA adducts, which if left unrepaired generate
mutations leading to cancer initiation. NAT1 is related to several cancer types by
its ability to biotransform arylamine procarcinogens to active carcinogen forms.
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However recent findings suggest that human NAT1 activity is involved in cancer
by a still unknown mechanism independent of procarcinogen metabolism.
Research in cancer biology has provided insights into the connections of
NAT1 and cancer cell proliferation and invasiveness. Overexpressing human
NAT1 in non-transformed breast epithelial cells, HB4a, resulted in increased
growth and survival. These modified cells also showed a resistance to etoposide
treatment [8]. Calu3 cells, a colon carcinoma cell line, that are resistant to
gemcitabine have higher expression of NAT1 [9]. In a majority of human
immortalized cells assayed there has been endogenous NAT1 expression/activity
observed [10]. The use of a lentiviral shRNA expression system for human NAT1
knockdown in a human breast cancer cell line, MDA-MB-231, caused a decrease
in cell proliferation and invasiveness [11, 12]. Similarly, NAT1 knockdown in a
human colon cancer cell line, HT-29 showed increased cell-cell contact inhibition
[13]. Up-regulation of E-cadherin was associated with knockdown of human
NAT1, but there was no change in the transcription factors Snail, Twist, or Slug
[13, 14]. Use of a small molecule inhibitor, Rhod-o-hp, specific for human NAT1
showed that inhibition in MDA-MB-231 cells stops cell proliferation, inhibited
anchorage-independent growth, and reduced the invasiveness of the cell [11]. All
the cell culture experiments indicate that human NAT1 plays some role in cancer
cell proliferation and survival.
Microarray data on many different types of breast cancer showed NAT1
expression was clustered with estrogen receptor expression [15, 16]. This
correlation between positive estrogen receptor (ER) status and human NAT1 was
2

confirmed by additional microarray studies [17-20]. Immunohistochemistry
showed higher human NAT1 levels in ER+ breast cancer samples when
compared to ER- breast cancer [8]. Expression also is affected by the deletion of
NAT1’s chromosome region in some cancers. The deletion may explain why
some cancer subtypes have low expression of NAT1 [21]. Tumors, characterized
based on which breast tissue the tumor arose from, showed luminal breast
cancers with higher NAT1 expression than basal breast cancer [16, 22, 23]. A
significant correlation has been observed between breast carcinomas expressing
the highest levels of NAT1 and those that metastasized to the bone [24]. Also,
elevated human NAT1 mRNA level has been shown to be associated with more
invasive breast cancers [25]. All this evidence for the relationship of NAT1 with
some subtypes of breast cancer has led some to state a possible role of NAT1 in
classifying cancer molecular subtypes.
Human populations exhibit different NAT1 variant haplotypes. The
reference haplotype is termed NAT1*4. NAT1*10 is known as one of the most
common variant haplotypes. NAT1*10 is presently defined by two SNPs
1088T>A

(rs1057126)

and

1095C>A

(rs15561)

in

the

3’

UTR

(http://nat.mbg.duth.gr). NAT1*10 is associated with increased NAT1 activity in
human bladder [26], colon [27], and liver [28]. NAT1*10 also is associated with
higher cancer risk in some types of cancer. NAT1*10 has been associated with
higher risk of developing cancer in the breast [29], colon/rectum [30, 31], lung
[32], pancreas [33], and urinary bladder [34]. However, other studies have
reported no association between NAT1*10 and cancer risk [35, 36].
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NAT1*14B is the most common variant allele that is associated with a
reduced acetylator activity. Allelic frequencies in American, German, French, and
Canadian populations are less than 5% [7]. However the allelic frequency of
NAT1*14B in the Lebanese population is about 24% [37]. NAT1*14B is defined
presently by a SNP of nucleotide G560A (rs4986782), which is located in the
open reading frame (ORF) (http://nat.mbg.duth.gr). G560A results in an amino
acid substitution R187Q. The arginine for glutamine substitution is thought to
destabilize the NAT1 structure. The use of homology modeling predicts that the
substitution affects NAT1 binding of acetyl-coenzyme A, active site acetylation,
catalytic activity, and substrate specificity [38]. NAT1*14B is associated with
smoking-induced cancer [39]. 4-Aminobiphenyl (ABP) DNA adducts are elevated
in cells that have been stably transfected with NAT1*14B compared with cells
transfected with NAT1*4 (considered the wildtype allele) [40].
In summary human NAT1 is involved in cancer cell proliferation and
survival. Human NAT1 has been found to correlate with aggressive forms of
cancer and estrogen receptor positive breast cancer. Human NAT1 haplotypes
that have the highest activity stand at a higher risk for certain types of cancer.
This evidence shows that NAT1 has a role in cancer, but the exact mechanism of
how it is involved is unknown.
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CHAPTER II
FOLATE-DEPENDENT HYDROLYSIS OF ACETYL-COENZYME A BY
RECOMBINANT HUMAN AND RODENT ARYLAMINE NACETYLTRANSFERASES
INTRODUCTION

Arylamine N-acetyltransferases (NATs) are phase II cytosolic isoenzymes
responsible for the metabolism of arylamine and N-hydroxylarylamine drugs and
xenobiotics [41]. The isoenzymes catalyze the transfer of the acetyl group from
acetyl-coenzyme A (AcCoA) to the exocyclic amine of an arylamine (Nacetylation) or the hydroxylated amine of an N-hydroxylated arylamine (Oacetylation) [42-44]. NATs are able to bioactivate procarcinogens like 4aminobiphenyl (ABP), a component of cigarette smoke [41]. Also, NATs
metabolize various pharmaceuticals, such as the antibacterial (sulfonamides),
antitubercular (isoniazid), and antiarrhythmic (procainamide) drugs [45-47].
Understanding N-acetyltransferase function, expression, and regulation aids in
predicting

individual

drug

toxicities

or

individual

tissue-specific

cancer

susceptibilities associated with environmental and/or occupational carcinogen
exposures.
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Amino acid residues at positions 125, 127, and 129 determine substrate
specificity of the 290 amino acid NAT1 protein [48]. Comparison of the amino
acids at the three mentioned positions in rat Nat2 and mouse Nat2 with human
NAT1, shows they share all three amino acids (Phe125, Arg127, and Tyr129).
However hamster Nat2 shares only two out of three amino acids (Phe125 and
Arg127) with human NAT1. This shared amino acid similarity suggests that these
NATs will have similar substrate specificity. The C-terminus undecapeptide tail of
the NATs controls the hydrolysis of AcCoA [49]. The C-terminus undecapeptide
tail of rat, mouse, and hamster Nat2 and human NAT1 share 100% identical
amino acids suggesting they are orthologs. Conversely rodent Nat1 and human
NAT2 do not align as well as rodent Nat2 and human NAT1. Only rat Nat1
(Tyr125, Ser127, and Tyr129) shares a single similar amino acid for the active
site in human NAT2 (Ser125, Ser127, Ser129). The mouse and hamster Nat1
(Tyr125, Gly127, Tyr129) share the same active site amino acids with each
other, but do not share any similarity to human NAT2. The C-terminus
undecapeptide tails for rodent Nat1 and human NAT2 also do not have much in
common. Rodents have an active Nat3 enzyme, unlike humans [1, 50].

N-acetyltransferases have been shown to play a role in development [51].
It has been proposed that human NAT1 influences folate homeostasis and thus,
affects neural tube development [52]. Human NAT1 acetylates the folate
catabolite, para-aminobenzoyl-1-glutamate [53]. Recent studies report that
human NAT1 and mouse Nat2 hydrolyze AcCoA into acetate and coenzyme A in
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a folate-dependent fashion [54], a previously unknown function (figure 2.1). In
this chapter, our goal was to confirm these findings and determine the apparent
Michaelis-Menten kinetic constants (Vmax and Km) of the folate-dependent
AcCoA hydrolysis for human NAT1/NAT2 and the rodent analogs rat Nat1/Nat2,
mouse Nat1/Nat2, and hamster Nat1/Nat2. We also compared apparent Vmax
values for AcCoA hydrolysis to N-acetylation of the substrate para-aminobenzoic
acid (PABA).

7

FIGURE 2.1

Figure 2.1. NAT1 enzymatic reactions are AcCoA-dependent N-acetylation of
arylamine substrate (A) and folate-dependent hydrolysis of AcCoA in absence of
arylamine acceptor substrate (B).
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MATERIALS AND METHODS

Arylamine N-acetyltransferases Recombinant Expression
Methods for the cloning and expression of the recombinant human and
rodent arylamine N-acetyltransferases have been reported in previous
publications from our laboratory for human [55], rat [56], mouse [57], and
hamster [58, 59]. In brief, JM105 Escherichia coli strain was transformed with
NAT containing pkk223-3 plasmid. The transformed JM105 E. coli was picked as
a single colony and cultured overnight in 50 ml LB media containing ampicillin
(100 µg/ml) at 37 °C. The following day, 4 ml of the overnight culture was added
to 200 ml fresh sterile LB media containing ampicillin (100 µg/ml) and grown until
the optical density (OD600nm) reached 0.4-0.6. Expression of N-acetyltransferases
was

induced

by

addition

of

isopropyl

β-D-thiogalactopyranoside

(final

concentration 1 mM) for 3 h. Cells were harvested by centrifugation at 5000 x g
for 10 min at 4 °C and the cell pellet was suspended in 10 ml of ice-cold 20 mM
sodium phosphate pH 7.4, 1 mM dithiothreitol, 1 mM EDTA, 0.2% triton-x-100,
100 µM phenylmethylsulfonyl fluoride, 1 µM pepstatin A, and 1 µg/ml aprotinin.
The solution was sonicated on ice 6 times for 30 sec. The lysate was centrifuged
at 15,000 x g for 20 min at 4 °C. Aliquots of supernatant were stored at -80 °C
until use.
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PABA N-acetylation Assays
PABA N-acetylation assays were done as previously described [60].
Briefly, recombinant lysate was added to a mixture of PABA (Sigma Aldrich) and
AcCoA (Amersham Biosciences), whose final concentrations in the reaction were
150 µM and 400 µM, respectively. The mixture was incubated at 37 °C for 10
min, after which the reaction was quenched with 1/10 volume of 1 M acetic acid.
Precipitated proteins were removed by centrifugation. Supernatants were
injected on a C18 column and reaction substrates and products separated and
quantitated

using

Beckman

System

Gold

high

performance

liquid

chromatography (HPLC).

AcCoA Hydrolysis Assays
Recombinant lysates were added to folate (Sigma-Aldrich) and AcCoA.
Initial reactions were carried out at 37 °C with fixed concentrations of folate (500
µM) and AcCoA (400 µM) to determine appropriate enzyme lysate dilutions for
subsequent reactions. Next, reactions were performed to determine MichalisMenton constants for AcCoA. Reactions were done at 500 µM folate and varying
AcCoA concentrations from 0 µM to 400 µM. The third set of reactions was done
with AcCoA fixed at 400 µM for mouse and hamster and 200 µM for human and
rat with folate concentrations varied between 0 and 400 µM. Control reactions
were done with the same enzyme and AcCoA concentration but no folate. The
amounts of CoA produced in the minus folate reactions were subtracted from
reactions containing folate to determine folate-dependent hydrolysis.
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Recombinant human NAT1 lysates were used to compare the ability of
AcCoA hydrolysis dependent on folate analogs methotrexate (MTX) (Sigma
Aldrich) and dihydrofolate (DHF) (Sigma Aldrich). Reactions were carried out at
37 °C with fixed concentrations of folate/MTX/DHF (300 µM) and AcCoA (500
µM) for 10 mins. Control reactions were done with the same enzyme and AcCoA
concentration but no folate analogs. The amounts of CoA produced in the minus
folate reactions were subtracted from reactions containing folate to determine
folate-dependent hydrolysis.

The reaction mixtures were incubated at 37 °C for 10 min, after which the
reaction was quenched by adding 1/10 volume of perchloric acid (15% w/v). The
precipitated protein was removed by centrifugation and the supernatant was
injected onto a C18 reverse-phase HPLC column (250 mm × 4 mm; 5 µM pore
size). Reactants and products were separated and quantitated by HPLC.
Separation of CoA, acetyl CoA, and folate was achieved using a linear gradient
of 100% 55 mM sodium phosphate pH 4.0: 0% methanol to 0% 55 mM sodium
phosphate pH 4.0: 100% methanol over 20 min and was quantitated by
absorbance at 260 nm. The limit of detection for CoA was 0.05 nmoles/min/mg of
protein.

Inhibition of PABA N-acetylation Activity with Folate Analogs
Recombinant human NAT1 lysates were added to a mixture of AcCoA
(400 µM), with varying folate/MTX (0, 100, 200, 300, 400, 500 µM), and varying
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PABA (0, 50, 100, 200, and 400 µM). The mixtures were incubated at 37 °C for
10 min, after which the reaction was quenched with 1/10 volume of 1 M acetic
acid. Precipitated proteins were removed by centrifugation. Supernatants were
injected on a C18 column and reaction substrates and products separated and
quantitated

using

Beckman

System

Gold

high

performance

liquid

chromatography (HPLC) as described above.

Statistics
All the data are shown as mean ± SEM from three separate
determinations. The Michaelis-Menten constants (Km and Vmax) were
determined by nonlinear regression of the Michaelis-Menten equation (GraphPad
Software, Inc, San Diego, CA)
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RESULTS
Michaelis-Menton Saturation Curves for AcCoA Hydrolysis
AcCoA hydrolysis with (figure 2.2, solid line) or without (figure 2.2, dash
line) the addition of folate (both in the absence of any arylamine NAT1 substrate)
was determined for recombinant human NAT1 and rodent Nat2. Some hydrolysis
of AcCoA to form CoA was observed in the absence of folate (figure 2.2). Since
this folate-independent hydrolysis of AcCoA to form CoA was also observed in
bacterial lysates from recombinantly expressed vector controls, this folateindependent hydrolysis of AcCoA was subtracted from folate-dependent AcCoA
hydrolysis rates in the subsequent measurements described below.

AcCoA Hydrolysis and N-acetylation Activities of Recombinant
Human NAT1 and NAT2
For human NAT1 the apparent Vmax and Km values determined for
AcCoA in the AcCoA hydrolysis reaction were 111 ± 13 nmoles/min/mg protein
and 54.3 ± 20.5 µM, respectively (figure 2.3A, solid line). For human NAT1 the
apparent Vmax and Km values determined for folate in the AcCoA hydrolysis
reaction were 200 ± 18 nmoles/min/mg protein and 85.2 ± 21.5 µM, respectively
(figure 2.3A, dash line). Initial rate constant for PABA N-acetylation activity for
recombinant human NAT1 was 20300 ± 1720 nmoles/min/mg protein. Human
NAT2 AcCoA hydrolysis activity was below the level of detection (0.05
nmoles/min/mg of protein).
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FIGURE 2.2

Figure 2.2. Michaelis-Menton saturation curves for AcCoA hydrolysis with
(circles with solid line) or without (squares with dashed line) 500 µM folate (with
no arylamine substrate present). Hydrolysis activity was catalyzed by human
NAT1 (A) and rodent Nat2s (B-D). Data points represent results from three
separate determinations with mean ± SEM.
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AcCoA Hydrolysis and N-acetylation Activities of Recombinant Rat
Nat1 and Nat2
For rat Nat2 the apparent Vmax and Km values determined for AcCoA in
the AcCoA hydrolysis reaction were 13.5 ± 2.6 nmoles/min/mg protein and 126 ±
60 µM, respectively (figure 2.3B, solid line). For rat Nat2 the apparent Vmax and
Km values determined for folate in the AcCoA hydrolysis reaction were 7.61 ±
0.78 nmoles/min/mg protein and 29.5 ± 14.0 µM, respectively (figure 2.3B, dash
line). Initial rate constant for PABA N-acetylation activity for recombinant rat Nat2
was 3030 ± 274 nmoles/min/mg protein. Rat Nat1 AcCoA hydrolysis activity was
below the level of detection (0.05 nmoles/min/mg of protein).

AcCoA Hydrolysis and N-acetylation Activities of Recombinant
Mouse Nat1 and Nat2
For mouse Nat2 the apparent Vmax and Km values determined for AcCoA
in the AcCoA hydrolysis reaction were 130 ± 9 nmoles/min/mg protein and 88.3 ±
18.3 µM, respectively (figure 2.3C, solid line). For mouse Nat2 the apparent
Vmax and Km values determined for folate in the AcCoA hydrolysis reaction
were 120 ± 14 nmoles/min/mg protein and 77.1 ± 27.9 µM, respectively (figure
2.3C, dash line). Initial rate constant for PABA N-acetylation activity for
recombinant mouse Nat2 was 32600± 1170 nmoles/min/mg protein. Mouse Nat1
AcCoA hydrolysis activity was below the level of detection (0.05 nmoles/min/mg
of protein).
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AcCoA Hydrolysis and N-acetylation Activities of Recombinant
Hamster Nat1 and Nat2
For hamster Nat2 the apparent Vmax and Km values determined for
AcCoA in the AcCoA hydrolysis reaction were 200 ± 13 nmoles/min/mg protein
and 164 ± 24 µM, respectively (figure 2.3D, solid line). For hamster Nat2 the
apparent Vmax and Km values determined for folate in the AcCoA hydrolysis
reaction were 186 ± 5 nmoles/min/mg protein and 94.0 ± 6.5 µM, respectively
(figure 2.3D, dash line). Initial rate constants for PABA N-acetylation activity for
recombinant hamster Nat2 was 20700 ± 1350 nmoles/min/mg protein. Hamster
Nat1 AcCoA hydrolysis activity was below the level of detection (0.05
nmoles/min/mg of protein).

Comparison of AcCoA Hydrolysis to PABA N-acetylation
Human NAT1 and rodent Nat2 lysates were able to N-acetylate PABA.
The percentages of the AcCoA hydrolytic activity (Vmax) for human NAT1 and
rodent Nat2 lysates were 0.25 to 1% relative to the initial rate constant for PABA
N-acetylation catalyzed by the same enzyme (table 2.1).
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FIGURE 2.3

Figure 2.3. Michaelis-Menton saturation curves with various concentrations of
AcCoA (solid line) and folate (dashed line) for human NAT1 (A), rat Nat2 (B)
mouse Nat2 (C) and hamster Nat2 (D). Hydrolysis activity in nmol/min/mg protein
is plotted on the ordinate versus substrate concentration on the abscissae. Folate
concentration was fixed at 500 µM for AcCoA Vmax and Km determinations.
AcCoA concentration was fixed at 200 µM for human NAT1 and rat Nat2 and 400
µM for mouse Nat2 and hamster Nat2 folate Vmax and Km determinations. Data
points represent mean ± SEM from three separate determinations.
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Table 2.1 - Comparisons of PABA N-acetylation and AcCoA hydrolysis by recombinant human NAT1 and rodent Nat2
enzymes.
AcCoA Hydrolysis
Apparent Vmax (nmol/min/mg)
AcCoA

Folate

Apparent hydrolytic
PABA N-acetylation
(nmol/min/mg)

Vmax/PABA acetylation
AcCoA (%)

Folate (%)

Human

NAT1

111 ± 13

200 ± 18

20300 ± 1720

0.547%

0.985%

Rat
Mouse

Nat2
Nat2

13.5 ± 2.6
130 ± 9

7.61 ± 0.78
120 ± 14

3030 ± 274
32600 ± 1170

0.446%
0.399%

0.251%
0.368%

Hamster

Nat2

200 ± 13

186 ± 5

20700 ± 1350

0.966%

0.899%
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Recombinant Human NAT1 AcCoA Hydrolysis Activity with Folate,
MTX, and DHF
Human NAT1 hydrolyzed AcCoA in the presence of folate with a rate of
104 ± 10.2 nmoles/min/mg protein (figure 2.4B). Human NAT1 hydrolyzed
AcCoA in the presence of DHF at a rate of 85.6 ± 9.13 nmoles/min/mg protein
(figure 2.4B). Human NAT1 hydrolyzed AcCoA in the presence of the folate
analog MTX at a very low rate of 2.50 ± 0.920 nmoles/min/mg protein (figure
2.4B). Folate-and DHF-dependent hydrolysis rates did not differ significantly
(p>0.05) from each other but both were significantly (p<0.001) elevated
compared to the level of MTX-dependent hydrolysis (figure 2.4B).

Inhibition of N-acetylation of PABA by Recombinant NAT1 with
Folate and MTX
Increasing the folate concentrations served to inhibit human NAT1 PABA
acetylation activity in a dose-dependent manner (figure 2.5A). Additionally the
increasing MTX concentrations served to inhibit the amount of acetylated PABA
produced by human NAT1 (figure 2.5B). The IC50’s for folate and MTX were
76.9 and 127 µM respectively (figure 2.5C and 2.5D).
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FIGURE 2.4
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Figure 2.4. The chemical structures (A) depicting folate, DHF, and MTX. Level of
AcCoA hydrolysis catalyzed by NAT1 with the addition of folate, MTX, and DHF
(B). MTX had significantly lower level of activity than folate or DHF. Data points
represent mean ± SEM from three separate determinations. The number of
asterisks corresponds to the p-value: *** = p <0.001.

20

FIGURE 2.5
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Figure 2.5. Michaelis-Menton curves showing inhibition by folate (A) or MTX (B)
on NAT1 PABA acetylation activity with increasing PABA concentration. The
concentrations of folate and MTX are 0, 100, 200, 300, 400, and 500 µM.
Folate (C) and MTX (D) inhibit PABA acetylation activity, when PABA is held
constant at 800 µM. Data points represent mean ± SEM from three separate
determinations.
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DISCUSSION
Folate is a water soluble B vitamin found in various foods (leafy green
vegetables, organ meat, etc.), and is commonly used to fortify foods. Commercial
fortification was mandated to prevent developmental defects in early fetal
development. However, of growing interest and experimentation is whether folate
levels in the body and folic acid supplementation affects tumor induction and
progression [61].

Our study has confirmed that human NAT1 and the rodent ortholog mouse
Nat2 are capable of AcCoA hydrolysis in the presence of folate but absence of
xenobiotic substrate (e.g. PABA) as shown by Laurieri et al. [54]. This study also
confirmed that folate is not consumed in the hydrolysis reaction and that human
NAT2 and mouse Nat1 do not perform this reaction to any significant degree. In
addition, we have shown that hamster and rat Nat2 enzymes also catalyze this
AcCoA hydrolysis, while the hamster and rat Nat1 has no detectable AcCoA
hydrolysis activity. A new methodology was developed in the study to measure
the level of CoA and AcCoA by HPLC. We determined the Michaelis-Menton
kinetic constants (Vmax and Km) for both AcCoA and folate using human NAT1
as well as three rodent Nat2 enzymes.

Human NAT1 had Vmax and Km values similar to hamster and mouse
Nat2 but different from rat Nat2 for both varying AcCoA and folate
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concentrations. Also, when comparing Vmax and Km values for folate and
AcCoA among the individual human and rodent enzymes they also appeared to
be surprisingly similar. The Vmax for AcCoA hydrolytic activity was less than 1%
of the PABA N-acetylation activity for the same enzyme. The total body content
of folate is estimated to be 10 to 30 mg; about half of this amount is stored in the
liver and the remainder is in blood and body tissues [62]. Erythrocyte folate
concentrations in the USA and Canada recently were reported from 0.5 to 2.5
nmol/L but varied with assay method, diet and supplementation. Modest
correlations recently were reported between plasma and breast folate
concentrations suggesting that plasma levels may not predict concentrations of
folate in various tissues [63]. Future studies with NAT2 knock out mice [52] or
congenic Nat2 rapid and slow acetylator rats [64] may help to determine whether
changes in level of human NAT1 (rodent Nat2) expression could affect AcCoA
levels in vivo and thus possibly affect cellular metabolism. The next chapter
describes congenic rat embryonic fibroblasts (REFs) used to compare
endogenous AcCoA levels. Slow acetylator congenic REFs showed higher
endogenous AcCoA levels than the rapid acetylator congenic REFs [65].

Folate is commonly considered to have a low abundance within the
mammalian cell, being reduced to dihydrofolate (DHF) upon entering the cell.
DHF is then reduced further resulting in other folate derivatives. Derivatives past
DHF are considered unstable and are not readily, commercially available with a
high level of purity. The instability of endogenous folate compounds makes the
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measurement of AcCoA hydrolysis dependent on endogenous folate compounds
complex. Fortunately, DHF is commercially available at 90% or more purity and
moderately stable. Human NAT1 is able to hydrolyze AcCoA in the presence of
DHF similar to folate, but not with an analog for folate and DHF, MTX.
Structurally DHF has one additional hydrogen compared to folate. Folate and
DHF compared to MTX differ mainly by the addition of one methyl group and an
amine group. MTX being unable to significantly stimulate AcCoA hydrolysis,
raises the questions of whether MTX is able to interact with the active site of
NAT1 and how similar endogenous folate derivatives stimulate AcCoA hydrolytic
activity by NAT1.

While MTX is almost unable to support the hydrolysis of AcCoA by NAT1,
it is able to inhibit the N-acetylation of PABA like folate (figure 2.5B). The similar
inhibition abilities of folate and MTX suggest that both folate and MTX are able to
interact with the active site. This interaction blocks substrates from entering the
deep pocket of the NAT1 enzymatic active site. The shared interaction with the
active site leaves the question, what chemical structural elements in folate allow
for the release the acetyl group from the acetylated cysteine since MTX is unable
to perform a similar function.

In summary, our results are consistent with the possibility that human
NAT1 and its rodent Nat2 orthologs regulate endogenous AcCoA levels in a
folate-dependent reaction. The results suggest associations of human NAT1
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activity with disease or tumor progression may be related to regulation of AcCoA.
The regulation of AcCoA levels will be analyzed in the following chapters. Further
studies are needed to explore how some folate compounds support the
hydrolysis of AcCoA by human NAT1.
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CHAPTER III
CONGENIC RATS WITH HIGHER ARYLAMINE N-ACETYLTRANSFERASE 2
ACTIVITY EXHIBIT GREATER CARCINOGEN-INDUCED MAMMARY TUMOR
SUSCEPTIBILITY INDEPENDENT OF CARCINOGEN METABOLISM
INTRODUCTION
Human arylamine N-acetyltransferase 1 (NAT1) is a cytosolic isoenzyme
responsible

for

environmental

the

and

N-acetylation
occupational

of

arylamine

carcinogens

such

xenobiotics,
as

including

4-aminobiphenyl

(ABP)[41]. NAT1 is located on the short arm of chromosome 8 (8p22) and is
expressed in nearly all human tissues [2, 3]. NAT1 catalyzes both O-acetylation
and N-acetylation. One role for NAT1 in carcinogenesis is its ability to
biotransform arylamine procarcinogens to active carcinogens [66]. Recent
findings in vitro suggest that NAT1 activity level also may influence cancer cell
proliferation and survival [8, 10, 11, 13].

NAT1 activity is modified by genetic polymorphism, but also can be
regulated by microRNA, epigenetic, and/or translational and post-translational
control features [67-70]. NAT1 transcript levels are regulated by extracellular
stimuli acting on glucocorticoid receptor or androgen receptor [71, 72]. Exposure
to NAT1 substrates can increase NAT1 degradation [69, 70]. Some
polymorphisms in humans destabilize the enzyme, leading to greater
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polyubiquitin-dependent

degradation

[69].

NAT1*10,

the

most

common

haplotype, is associated with increased NAT1 activity in human bladder [26],
colon [27], and liver [28]. NAT1*10 has been associated with higher risk of
developing cancers of the breast [29], colon/rectum [30, 31], lung [32], pancreas
[33], and urinary bladder [34]. However, other studies have reported no
association between NAT1*10 and cancer risk [35, 36].

Rat arylamine N-acetyltransferases are similar in sequence and function
to human N-acetyltransferases [48, 50, 73]. Rat models have been used for the
study of arylamine N-acetyltransferases [73-75]. Rat NAT2 and human NAT1
active sites both contain Phe125, Arg127, and Tyr129, consistent with their
similar arylamine substrate selectivity [48]. The C-terminal undecapeptide, which
is involved in controlling acetyl-coenzyme A (AcCoA) hydrolysis [49], is 100%
identical when comparing rat NAT2 and human NAT1. Rat Nat2 and human
NAT1 are orthologs as shown by their amino acid sequence similarity (figure
3.1).

Rats, like humans, have different NAT2 haplotypes. Homozygous rapid
(F344) and slow (WKY) acetylator inbred rats have been characterized as rapid
and slow NAT2 acetylators, respectively [75, 76]. Slow acetylator WKY inbred
rats are homozygous for a rat Nat2 allele with four single nucleotide
polymorphisms (SNPs): G361A (Val121→ Ile), G399A (synonymous), G522A
(synonymous), and G796A (Val266→ Ile), as compared to the Nat2 allele in the
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F344 strain rapid-acetylator Nat2 allele [56] (figure 3.1). These two inbred rat
stains were used in the development of congenic F344.WKY rats with either high
(rapid) or low (slow) NAT2 activities [64].
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FIGURE 3.1
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Figure 3.1. Amino acid sequence comparison between human NAT1 and rat
Nat2. The gray highlighting indicates areas were the amino acids differ between
the two enzymes. The two enzymes are 83 % identical to each other. The yellow
highlighted regions indicate the areas of importance to the enzymes, the cterminus tail and the three critical amino acids in the active site. The two
enzymes share 100% identity in the active site and c-terminus tail. In the rat
amino acid sequence there are two underlined amino acids, Val121 and Val266.
Both valines are isoleucines in the slow phenotypic rats, whereas they are
valines in rapid, wildtype, rats.
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Breast tumors have been induced for several decades with the
administration of methylnitrosourea (MNU). MNU is a simple alkylating agent,
which places a methyl group on oxygen and nitrogen of macromolecules, like
DNA. It has been shown previously that sexually immature F344 rats (at 3 weeks
of age) are more susceptible to mammary carcinogenic effects from MNU than
mature rats (8 weeks of age) [77].

The mechanism for how MNU causes cancer is by DNA damage resulting
from the alkylation of nitrogen and oxygen in DNA leading to mutations. N7alkylguanine, N3-alkyladenine, and O6-alkylguanine account for 68%, 8%, and
7.5% of total methylation after MNU treatment, respectively [78]. The N7 atom of
guanine is the most vulnerable site for attack by alkylating agents; however N7alkylguanine alone has no pronounced mutagenic and cytotoxic effect [79].
Alkylation of the N7 atom does cause chemical instability at the N-glycosidic
bond, causing spontaneous abasic/apurinic sites to form. Abasic sites also form
in the repair of N7-alkylguanine by N-alkylpurine DNA-glycosylases, enzymes in
the BER pathway. The mutagenic and toxic effects of abasic sites have been well
described previously [80]. N3-alkyladenine is not particularly mutagenic, but it is a
cytotoxic DNA lesion because it is able to block replication and able to generate
abasic sites [79]. N3-alkyladenine has been shown to cause sister chromatid
exchange, chromosome gaps and breaks, S phase arrest, accumulation of p53,
and apoptosis in mammalian cells [81]. O6-alkylguanine is the primary mutagenic
lesion under most conditions of alkylation damage to the genome causing G →A
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transitions after two replications [79, 82] (figure 3.2). In addition to the point
mutations following DNA replication, O6-alkylguanine can also result in mismatch
repair-mediated DNA recombination and cell death [83]. Repair by mismatch
repair system at O6-alkylG:T can form the “futile cycle”. The “futile cycle” occurs
when repair enzymes recognize mismatch of G:T and remove the newly
incorporated thymidine opposite of O6-alkylguanine. Then, the sequence is
replicated again and the O6-alkylguanine preferentially pairs with thymine, once
more, thus reinitiating the repair and replication cycle [79, 82, 84, 85]. This
persistent cycling of mismatch repair can generate a stabilized nick or gap in one
strand of DNA, which may activate damage signaling pathways and DNA
recombination [84]. Even with this futile cycling, it has been found that O6alkylguanine lesions went from being 10% mutagenic in cells with repair
capability to nearly 100% mutagenic in cells without DNA repair abilities [86]. In
total the resulting alkylation of nitrogen and oxygen in DNA by a simple direct
acting carcinogen, MNU, shows how cancer can result without rat NAT2 playing
a direct metabolizing role.

31

FIGURE 3.2

Figure 3.2. Mechanistic diagram for how MNU damages DNA. MNU alkylates
guanine, which can be repaired immediately by O6-alkylguanine-DNA
alkyltransferase (MGMT), also known as O6-alkylguanine-DNA alkyltransferase
(AGT). However if not repaired before replication, translesion DNA synthesis
(TLS) will be done. TLS mismatches the nucleotide causing three possible
pathways. The one on the left is that another TLS occurs resulting in a
permanent mutation that can allow the cell to survive. The second possibility is
on the right and is a direct signaling pathway that tells the cell to undergo
apoptosis. The middle one is where the mismatch repair pathway tries to correct
the mismatch of G:T and removes the newly incorporated thymidine opposite of
O6-alkylguanine. Then, the sequence is replicated again and the O6-alkylguanine
preferentially pairs with thymine, once more, thus reinitiating the repair and
replication cycle. This reoccurring cycling is termed the “futile cycle” Futile cycle
can generate a stabilized nick or gap in one strand of DNA, which can cause
replication fork collapse and a double strand DNA break (DSB). The DSB can be
repaired by non-homologous end-joining (NHEJ) pathways, which can lead to
cell survival but with mutations, sister chromatid exchange (SCE), or
chromosomal aberrations. If the DSB is not repaired, cellular programing will be
triggered to lead the cell into apoptosis. This figure has been modified from one
previously published by Fu et al [87].
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7,12-dimethylbenzanthracene

(DMBA)

is

a

polycyclic

aromatic

hydrocarbon compound that is known for its carcinogenic properties. DMBA is
extensively used in rodent models for breast, skin, and other cancers [88].
DMBA, similar to other polycyclic aromatic hydrocarbon compounds, requires
bioactivation to an active carcinogen. DMBA is initially metabolized by
cytochrome P450 to DMBA-3,4-oxide, then to DMBA-3,4-diol by epoxide
hydrolase, and finally metabolized again by cytochrome P450 to DMBA-3,4-diol1,2-epoxide [89, 90]. The enzymes responsible for this bioactivation of DMBA are
cytochrome P4501B1 (CYP1B1) and microsomal epoxide hydrolase (EPHX1)
[91]. CYP1B1 is thought of as the main enzyme in DMBA metabolism for humans
and rodents [92]. DMBA-3,4-diol-1,2-epoxide is the active metabolite of DMBA
that results in DNA adduct formation. The resulting DNA adducts are associated
with DNA mutations and malignant transformation [93, 94]. As with MNU, DMBA
has an established mechanism for cancer development without rat NAT2 playing
a direct metabolizing role.

In this chapter, rapid (F344.WKY-Nat2rapid) and slow (F344.WKY-Nat2slow)
acetylator rat strains were utilized to investigate mammary cancer risk following
the administration of methylnitrosourea (MNU) or 7,12-dimethylbenzanthracene
(DMBA), neither of which is biotransformed by rat NAT2 [89, 95-97]. The two
carcinogens are extensively researched and characterized. MNU is known to be
a direct acting carcinogen, which will eliminate any differences caused by
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metabolism of a pro-carcinogen. DMBA is a well characterized pro-carcinogen
that has no evidence of being metabolized by human NAT1 or rat NAT2.
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MATERIALS AND METHODS
Rapid and Slow Acetylator Rats Congenic at the Nat2 Locus
Rapid and slow acetylator Nat2 congenic Fischer 344 (F344.WKY) rats
were housed in the University of Louisville animal facility and the experiments
were reviewed and approved by the University’s Institutional Animal Care and
Use Committee. The construction of rapid and slow acetylator Nat2 congenic rats
was previously reported [64]. Briefly, F344 (homozygous Nat2 rapid) males were
mated to WKY (homozygous Nat2 slow) females to produce the obligate
heterozygous F1 generation. F1 females were then backcrossed with F344 males.
Heterozygous acetylator female progeny from each successive backcross were
identified by rat Nat2 genotype and were mated with F344 rapid acetylator males.
After ten generations of backcrossing, heterozygous acetylator brother/sister
progeny were mated to produce the homozygous rapid and slow acetylator
congenic rat Nat2 lines. The congenic F344.WKY rats have been confirmed for
rapid and slow acetylator phenotype across multiple tissues and substrates [64].

Methylnitrosourea Administration
Forty-two female rapid acetylator congenic rats and thirty-four female slow
acetylator congenic rats, at 3 weeks of age, were administered methylnitrosourea
(MNU; CAS#: 684-93-5)(Ash-Stevens, Detroit, MI) by a single intraperitoneal (IP)
injection of 50 mg/kg (10 mg/ml) solution dissolved in saline pH 5.0, acidified with
glacial acetic acid (figure 3.3) [98-100]. Six rapid and six slow acetylator control
female rats were injected with vehicle. During the twenty-three week experiment,
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one rapid (17 weeks) and two slow acetylator rats (18 and 18 weeks) were
euthanized due to tumor burden and/or size. These data were incorporated into
the statistical analysis.

Twenty-four rapid acetylator female congenic rats and thirty-three slow
acetylator female congenic rats, at 8 weeks of age, were administered MNU by a
single IP injection of 50 mg/kg (10 mg/ml) as above (figure 3.3). Three rapid and
four slow acetylator control female rats were injected with vehicle. During the
study one rapid female acetylator rat was euthanized (16 weeks) because of
tumor burden and/or size. This sample was included in the statistical analysis.
7,12-dimethylbenzanthracene Administration
Twenty-eight rapid acetylator female congenic rats and thirty-three slow
acetylator female congenic rats were given a single dose of 7,12dimethylbenzanthracene dissolved in sesame seed oil (DMBA; CAS#: 57-976)(Acros Organics, New Jersey, USA) (65 mg/kg) by oral gavage at 8 weeks of
age (figure 3.3)[101, 102]. Three rapid and three slow acetylator control female
rats were injected with vehicle. During the study four rapid female acetylator rats
were euthanized (14, 17, 20, and 21 weeks) because of weight loss or tumor
burden issues. Additionally six slow acetylator females were euthanized (9, 17,
14, 20, 21, and 21 weeks) for weight loss or tumor burden issues. These data
were still utilized for statistical analysis.
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FIGURE 3.3

Figure 3.3. Experimental design for chemical-induced tumor experiments. Top
shows the dosing of MNU at 3 weeks of age. The middle displays the dosing of
MNU at 8 weeks of age. The bottom depicts the dosing of DMBA at 8 weeks of
age.
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Weekly Monitoring of Animal Weight and Palpable Mammary Tumors
Rats were weighed weekly following carcinogen administration. Rats that
displayed bradykinesia/fatigue, a tumor size = 10% of body weight, or tumors that
were ulcerated (any break in skin observed) were euthanized. Rats were
palpated weekly. The number of weeks post-carcinogen exposure of first
palpable mammary tumor was recorded.

Mammary Tissue and Tumor Collection
Twenty-three weeks after administration of a carcinogen, rats were
euthanized by CO2 asphyxiation followed by cervical dislocation. The rats were
immediately dissected to count mammary tumors that were ≥3 mm in any
direction, collect samples, and record any abnormalities. Mammary tumor and
adjacent mammary-tissues were removed and fixed in 10% neutral buffered
formalin.

Pathology
Tissue samples described above were processed and stained by the
Special Procedure Laboratory at the University of Louisville. In brief, tissue was
paraffin embedded and sections cut at 5 µm. Sections were stained using
hematoxylin and eosin (H&E). H&E stained slides were evaluated and
categorized, based on histomorphology, into the following groups: Normal,
Benign, Low Grade Carcinoma In Situ (CIS), Intermediate Grade CIS, High
Grade CIS and Invasive Carcinoma. If a mammary tumor demonstrated multiple
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features of more than one category, the most malignant category was used for
classification. Rats with multiple tumors were categorized by the most severe
classification. These evaluations and classifications were performed blind to rat
treatment and phenotype.

Rapid and Slow Acetylator Rat NAT2 Recombinant Expression and
Enzymatic Activity
Recombinant rapid and slow acetylator rat NAT2 proteins were expressed
in JM105 E. coli as described [56, 103]. Total bacterial lysate protein
concentration was determined for each expression using the Bio-Rad protein
assay kit (Bio-Rad, Hercules, CA). Bacterial lysates were assayed for Nacetylation of para-aminobenzoic acid (PABA) and folate-dependent AcCoA
hydrolysis.

For determination of PABA N-acetylation activity, lysates (in triplicate)
were incubated with 1 mM AcCoA and 300 µM PABA for 10 min at 37°C, and the
reaction was stopped by addition of 1/10 volume of 1 M acetic acid. The reaction
tubes were centrifuged to remove precipitated protein, and supernatant was
injected onto a LiChrospher 100 RP-18 (125 mm X 4 mm; 5 µm) reverse-phase
column. Reactants and products were separated by high-performance liquid
chromatography (HPLC)(Beckman Coulter, Fullerton, CA). N-Acetyl-PABA
product was quantitated by its absorbance at 280 nm as described [103].

39

Bacterial lysates were assayed for folate-dependent AcCoA hydrolytic
activity as reported [103]. In brief, lysates (in triplicate) were incubated with 500
µM AcCoA in the presence or absence of 300 µM folate for 10 min at 37°C, and
the reaction was quenched by adding 1/10 volume of perchloric acid (15% w/v).
The precipitated protein was removed by centrifugation and the supernatant was
injected onto a C18 reverse-phase HPLC column (250 mm X 4 mm; 5 µm).
Reactants and products were separated and quantitated by HPLC. Separation of
CoA, acetyl CoA, and folate was achieved using a linear gradient of 100% 100%
55 mM sodium phosphate pH 4.0: 0% methanol to 0% 55 mM sodium phosphate
pH 4.0: 100% methanol over 20 mins and was quantitated by absorbance at 260
nm. The amounts of CoA produced in the minus folate reactions were subtracted
from reactions containing folate to determine folate-dependent hydrolysis.
Control reactions without the addition of protein lysate also were included. The
limit of detection for CoA was 0.05 nmoles/min/mg protein.
Rapid and Slow Congenic Rat Tissue Lysate Preparation and
Enzymatic Activity
Liver, lung, colon, and mammary tissues were collected from 8 week old
female rapid and slow NAT2 congenic rats. Tissues were homogenized in 20 mM
sodium phosphate (pH 7.4), 1 mM EDTA, 0.2% triton X-100, 1 mM dithiothreitol,
100 µM phenylmethanesulfonyl fluoride, 10 µg/ml aprotinin, and 1 µM pepstatin.
Homogenates were centrifuged at 15,000 x g for 10 min, and aliquots of
supernatants were stored at -80°C until used. Protein concentrations were
determined using the Bio-Rad protein assay kit.
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To measure PABA N-acetylation activity, reactions containing tissue lysate
(<2 mg of protein/ml), 300 µM PABA and 1 mM AcCoA were incubated at 37 °C
for 10 min. Reactions were terminated by the addition of 1/10 volume of 1 M
acetic acid. Activity was quantified by HPLC as described above.

To measure folate-dependent AcCoA hydrolytic activity, reactions
containing tissue lysate (<2 mg of protein/ml), 300 µM folate and 500 µM AcCoA
were incubated at 37 °C for 10 min. Reactions were terminated by the addition of
1/10 volume of perchloric acid (15% w/v). Activity was quantified by HPLC as
described above.

Rat Embryonic Fibroblasts Isolation
Rat embryonic fibroblasts (REFs) were isolated from congenic rats by
adapting procedures described previously for mouse embryonic fibroblasts [104].
Dams were euthanized by CO2 asphyxiation and cervical dislocation on E13.5
(13.5 days post copulation) and embryos removed by Caesarean section.
Embryonic brain tissue and organs were removed. The resultant tissue was
dissociated by gentle enzymatic digestion [0.05% trypsin (w/v) for 15 mins] and
cells were plated into 10 cm dishes (one embryo per dish) in DMEM (Dulbecco’s
modified Eagle’s medium; high glucose, Lonza, Walkersville, MD, USA)
supplemented with 10% FBS (fetal bovine serum), 2 mM L-glutamine, 100
units/ml penicillin, 100 mg/ml streptomycin and 0.25 mg/ml amphotericin.
Passaging was by cell dissociation from plates [0.05% trypsin (w/v) for 15 mins]
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and re-plating 5 x 105 cells on fresh 10 cm dishes. Resulting REF cell lines at
passage 4 were characterized for their PABA N-acetylation activities as
described above.

REFs Endogenous Cellular AcCoA Concentration Measurements
Endogenous acetyl-CoA levels within REFs were determined by HPLC.
On passage 4, the REFs were plated at 5 x 105 per 10 cm plate and allowed to
grow for 96 hours. After 96 hours, media were aspirated from each plate, and
washed with 5 ml phosphate-buffered saline (PBS). Then cells were gently
dissociated from the plate with 0.5 ml trypsin [0.05% (w/v) for 15 min]. Cells were
suspended in 4 ml of diluted complete media (20% medium and 80% PBS).
Aliquots of 0.5 ml were used to count the number of cells per ml. In the
subsequent steps all cells and lysates were kept on ice or in 4°C conditions.
Collected cells were washed with ice cold PBS, and transferred to a 1.5 ml
microcentrifuge tubes. The suspended cells were collected by centrifugation and
the supernatants discarded. Having removed any residual PBS, the cells were
lysed in 100 µl of ice-cold 5% 5-sulfosalicylic acid with a 1 ml BD Insulin Syringe
with permanently attached 28 gauge needle (BD Franklin Lakes, NJ, USA). The
cellular lysate was then centrifuged at 13,000 x g for 10 min. Supernatant was
filtered through a syringe filter (13 mm, 0.20 µm pore size). Filtrate was collected
and separated on a C18 reverse-phase HPLC column (250 mm × 4 mm; 5 µm
pore size). HPLC separation and quantitation of AcCoA was achieved using the
same method described above for folate-dependent AcCoA hydrolysis.
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Statistics
Weights were compared over time by a two-way analysis of variance
followed by Bonferroni post hoc test. Latency and incidence of first palpable
mammary tumors over time were tested by logrank (Mantel-Cox) test. MannWhitney tests were used to compare mammary tumor multiplicity. Terminal tumor
incidence was tested by a Fischer’s exact test. Enzymatic activities and
endogenous AcCoA concentrations were compared by unpaired t-tests. All
statistical tests were done using Prism software by GraphPad (La Jolla, CA).
Data are displayed and presented as the average ± standard error of mean
(SEM) for each respective group.
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RESULTS
Weight Gain
Rapid and slow acetylator congenic rats administered vehicle at either 3 or
8 weeks demonstrated normal weight gain. Initially, all MNU-treated rats
experienced hindered weight gain post administration, but then recovered to a
rate of weight gain similar to vehicle-treated rats. MNU-treated rats never
reached the same weight as the vehicle-treated counterparts (figure 3.4). No
statistically significant (p>0.05) differences in weight gain were noted between
MNU-treated rapid and slow acetylator congenic rats.

DMBA-treated rats displayed no initial hindrance in weight gain; however,
during the time following DMBA administration, DMBA-treated rats tended to
have lower body weight than vehicle-treated rats (figure 3.4). No statistically
significant (p>0.05) differences in weight gain were noted between DMBA-treated
rapid and slow acetylator congenic rats.
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FIGURE 3.4

Figure 3.4. Weekly body mass (mean grams ± SEM) of rapid and slow acetylator
Nat2 congenic rats post administration of specified carcinogen or vehicle control.
In all three panels squares represent rapid acetylator and circles represent slow
acetylator congenic rats. Filled-shapes represent vehicle-treated and unfilledshapes represent MNU or DMBA-treated. Weights for rats treated with MNU at 3
weeks of age (A). The difference between weights of the vehicle-treated and
MNU-treated is statistically significant by two-way ANOVA with Bonferroni post
hoc test (p<0.05). Weights for rats treated with MNU at 8 weeks of age (B). The
weights of the vehicle-treated and MNU-treated rats were statistically significant
by two-way ANOVA with Bonferroni post hoc test (p<0.05). Weights for rats
administrated DMBA at 8 weeks of age (C). The weights of the vehicle-treated
and DMBA-treated rats were not statistically significant by two-way ANOVA with
Bonferroni post hoc test (p>0.05). In all panels, weights of MNU/DMBA-treated
rats were not significantly different between rapid and slow NAT2 acetylator rat
strains.
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Palpable Mammary Tumor Latency and Incidence
As shown in figure 3.5, rapid acetylator congenic rats had significantly
shorter latency for development of their first palpable mammary tumor compared
to slow acetylator NAT2 congenic rats after administration of MNU in females
treated at either 3 or 8 weeks of age. Rapid acetylator rats showed significantly
higher tumor incidence compared to slow acetylator rats after MNU
administration at 3 or 8 weeks of age.

DMBA-treated rapid acetylator rats displayed a higher tumor incidence
over the course of the treatment than DMBA-treated slow acetylator rats,
although logrank test analysis provides a p-value (p=0.065) slightly greater than
our established p-value threshold of significance (p=0.050).
Terminal Mammary Tumor Incidence and Multiplicity
As shown in table 3.1, female congenic rats, administered MNU at 3
weeks of age, developed tumors in 66.7% of the rapid acetylator congenic rats
with an average 1.00 ± 0.17 tumors per rat. In contrast, tumors were found in
52.9% of slow acetylator congenic rats with an average of 0.67 ± 0.12 tumors per
rat. These mammary tumor incidence and multiplicity results were not
significantly different between rapid and slow acetylator rats administered MNU
at 3 weeks of age.
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FIGURE 3.5

Figure 3.5. Kaplan-Meier plot of palpable mammary tumors in congenic rats.
Onset of tumors in rats exposed to MNU at 3 weeks of age (A), MNU at 8 weeks
of age (B), and DMBA at 8 weeks of age (C). Squares illustrate rapid and circles
illustrate slow acetylator Nat2 congenic rats. Rapid acetylator congenic rats had
a significantly (p<0.05) shorter latency for development of first palpable
mammary tumor compared to slow acetylator congenic rats after MNU
administration at either 3 or 8 weeks of age. Similar findings were obtained after
DMBA administration at 8 weeks of age although the difference was not
significant (p=0.065)
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As shown in table 3.1, female congenic rats administered MNU at 8 weeks
of age developed tumors in 41.6% of rapid acetylators with 0.50 ± 0.14 average
tumors per rat. Slow acetylators developed tumors in 15.2% of those given MNU,
with 0.24 ± 0.12 tumors per rat. Thus, rapid acetylator rats exhibited significantly
higher mammary tumor incidence (p=0.035) and multiplicity (p=0.050) compared
to slow acetylator rats.

No other tissue/organ tumors besides mammary tumors were observed in
either MNU- or vehicle-treated rats. A few rats displayed discoloration of the
eyes, thought to be an onset of cataracts. Cataracts and retinal degradation can
occur in rats following MNU administration [105].

As shown in table 3.1, female congenic rats exposed to DMBA developed
mammary tumors in 76.0% of rapid acetylators with 1.20 ± 0.16 average tumors
per rat. Slow acetylators developed tumors in 43.3% of those given DMBA, with
0.57 ± 0.14 tumors per rat. Rapid acetylator rats had significantly higher
mammary tumor incidence (p=0.027) and multiplicity (p=0.004) compared to slow
acetylator rats. No other tissue/organ tumors besides mammary tumors were
observed in DMBA- or vehicle-treated rats.
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Table 3.1 - Mammary tumor totals in rapid and slow acetylator congenic rats administered MNU or DMBA

Treatment
Protocol
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MNU
3 weeks
MNU
3 weeks
MNU
8 weeks
MNU
8 weeks
DMBA
8 weeks
DMBA
8 weeks

Rats treated
Acetylator
and
phenotype
necropsied

Total
Total tumors
tumors per ratb,c

Total tumors per rat in
tumor- bearing ratsc

Rapid

42

28 (66.7%)

42

1.00 ± 0.17

1.50 ± 0.20

Slow

34

18 (52.9%)

23

0.67 ± 0.12

1.28 ± 0.11

Rapid

24

10 (41.6%)*

12

0.50 ± 0.14*

1.20 ± 0.20

Slow

33

5 (15.2%)*

8

0.24 ± 0.12*

1.60 ± 0.24

Rapid

25

19 (76.0%)*

30

1.20 ± 0.16**

1.58 ± 0.12

Slow

30

13 (43.3%)*

17

0.57 ± 0.14**

1.31 ± 0.17

a

Tumor incidence

b

Tumor multiplicity

c

Rats with tumors
(%)a

Mean ± SEM. Total mammary tumors differed significantly *(p < 0.05) ** (p < 0.01) between rapid and slow acetylator rats

Pathology
A majority of the mammary tumors that developed in carcinogen-treated
rats were classified as non-invasive (figure 3.6). More tumors classified as
benign were noted in rats administered MNU at 3 weeks compared to 8 weeks of
age (15% and 0%, respectively).

Among the rapid and slow congenic rat strains administrated MNU at 3
weeks of age, ~11% of tumors were classified as invasive carcinomas in the
rapid acetylators (3/28) versus none in the slow acetylators (0/18). Low grade
CIS tumors were the most common histomorphological classification of tumors in
both rapid and slow rat Nat2 congenic strains.

Rats administered MNU at 8 weeks of age exhibited similar percentages
of mammary tumors classified as low grade CIS in rapid (5/10) and slow (2/5)
acetylators. Mammary tumors classified as high grade CIS tumors were
observed in 3 rapid acetylator congenic rats (3/10), and the only tumor classified
as invasive was found in one slow acetylator rat (1/5).

In general, rats administered DMBA displayed a very similar distribution
pattern of tumor pathology. The rapid NAT2 congenic rats had more benign
tumors (4/19 or 21%) than slow NAT2 congenic rats (1/13 or 8%). The slow
congenic rats had a higher percentage of tumors with an invasive classification
than the rapid congenic rats (31% [4/13] vs 11% [2/19]).
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FIGURE 3.6

Figure 3.6. Photomicrographs of H&E stained slides depicting the criteria utilized
to classify tumors. Normal mammary tissue (a). Benign tumor (b) showing
proliferative disease with no cytologic atypia and minimal to no overgrowth of the
epithelial or myoepithelial component (black arrows). CIS lesions (c-e) with
overgrowth of the epithelial and/or myoepithelial component (red arrows). Low
grade CIS lesion (c) with low grade cytologic atypia and occasional mitoses or
single cell apoptosis. Intermediate grade CIS lesion (d) with intermediate to high
grade cytologic atypia with increased mitoses (blue arrows) or single cell
apoptosis. High grade CIS lesion (e) with intermediate to high grade cytologic
atypia with tumor necrosis (yellow dashed arrow) and increased mitoses (blue
arrows). Invasive carcinoma (f) with glands or single cells infiltrating through
stroma.
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Enzymatic Activities of Recombinant Rapid and Slow Rat NAT2
PABA N-acetylation velocities for rat arylamine N-acetyltransferase 2
catalyzed by recombinant rapid acetylator NAT2 was significantly (p=0.005)
higher than by recombinant slow acetylator NAT2 (figure 3.7A). The folatedependent AcCoA hydrolysis catalyzed by rat NAT2 was significantly (p=0.005)
higher for recombinant rapid acetylator NAT2 than recombinant slow acetylator
NAT2 (figure 3.7B).

Rapid and Slow Acetylator Rat NAT2 Activities in Tissue Lysates
The PABA N-acetylation activities of Nat2 congenic rats measured in
lysates from several tissue-types was significantly higher in rapid than slow
acetylators: liver (p<0.001), lung (p<0.001), colon (p=0.007), and mammary
gland (p<0.001) (figure 3.7C). The folate-dependent AcCoA hydrolysis was
significantly higher in rapid acetylator than slow acetylator lung (p=0.002) and
colon (p=0.002) (figure 3.7D). No detectable folate-dependent AcCoA hydrolysis
activity was observed in liver and mammary tissue lysates (threshold of detection
0.05 nmoles/min/mg protein).
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FIGURE 3.7

Figure 3.7. Rat NAT2 PABA acetylation (A, C) and folate-dependent AcCoA
hydrolysis activity (B,D). The same recombinant lysates were used in triplicate for
each activity (A, B).. Lysates of individual tissues collected from either 5 rapid
(closed bars) or 5 slow (open bars) acetylator NAT2 F344 congenic rats (C, D).
“ND” = not detectable. The number of asterisks corresponds to the p-value: *** =
p <0.001; ** = p < 0.01.
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NAT2 Activity and Endogenous AcCoA Concentrations in Isolated
Congenic REFs
The REFs isolated from the congenic rat strains were characterized for
their ability to acetylate PABA and their endogenous AcCoA concentrations after
the fourth passage. PABA N-acetylation in rapid NAT2 REFs was significantly
higher than in slow NAT2 REFs (p=0.002) (figure 3.8A). Endogenous AcCoA
concentrations levels in the rapid NAT2 REFs were lower compared to that of the
slow NAT2 REFs (p=0.003) (figure 3.8B).
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FIGURE 3.8

Figure 3.8. NAT2 activity and AcCoA level measured in rat embryonic fibroblasts
(REFs) from rapid and slow rats. Rapid NAT2 REFs (N=7) have a higher level of
PABA acetylation activity than slow NAT2 REFs (N=9) (A). The amount of AcCoA
per million cells is lower in rapid NAT2 REFs (N=8) than in slow NAT2 REFs
(N=10) (B). The number of asterisks corresponds to the p-value (**, p < 0.01).
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DISCUSSION
This study is the first to utilize a functional animal model to look at
tumorigenic differences between rapid and slow rat NAT2 activity using
carcinogens that do not require NAT2 activity for activation/deactivation. This
functional animal model mimics human populations. Rat NAT2 is the ortholog of
human NAT1. Genetic variants and other factors influence human NAT1 activity
levels. The NAT1*10 haplotype is associated with increased NAT1 activity in
human tissue samples [26-28]. Other polymorphic haplotypes encode a less
stable NAT1, leading to a decrease in enzymatic activity. Our results in Nat2
congenic rats suggest that human genetic variation resulting in differential NAT1
activity may influence human breast cancer. Furthermore, our findings suggest
that NAT1*10 human haplotypes may have a higher risk of breast cancer
compared to the reference NAT1*4 haplotype. Also, polymorphic variants that
decrease NAT1 activity would likely have a reduced cancer risk.

In the present study, we investigated whether chemical carcinogens
induced tumors more rapidly or in greater abundance in rapid than slow Nat2
congenic rat strains. MNU was administered at either a pre-pubescent age (3
weeks) or a post-pubescent age (8 weeks). Additionally DMBA was administered
at only post-pubescent age (8 weeks). We observed decreased latency and
increased incidence of palpable mammary tumors in congenic rapid acetylator
rats than in congenic slow acetylator rats treated with either MNU or DMBA.
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Terminal multiplicity and incidence also were higher in rapid than slow acetylator
rats administered MNU or DMBA.

The role of human NAT1 in cancer is not well understood, but the current
understanding of NAT1’s potential importance in cancer is expanding. Several
microarray studies have shown that elevated NAT1 expression is correlated with
estrogen receptor positive (ER+) breast cancer samples [8, 10, 16]. Human
NAT1 expression in breast cancer is predicted to be a valuable indicator for
antiestrogen responsiveness [106] and an indicator of a positive prognosis,
particularly in ER+ breast cancer [107]. Normal human mammary luminal
epithelial cell lines (HB4a) engineered to overexpress NAT1 continue growing
compared to normal HB4a cells that reach a growth plateau [8]. The present
study adds to the developing and complex narrative of NAT1 in cancer, by
providing the first animal model data that show an association between NAT1
activity levels and tumorigenesis independent of carcinogen metabolism.

Rapid acetylator rats displayed elevated risk of mammary tumors
compared to slow acetylator MNU-treated rats regardless of whether treatment
occurred when immature or mature. Pre-pubescent exposure to MNU, regardless
of NAT2 activity phenotype, resulted in greater palpable tumor incidence, as well
as increased terminal mammary tumor incidence and multiplicity (table 3.1 and
compare panels in figure 3.5). This increase with earlier age of MNU-exposure is
consistent with the known elevated breast cancer susceptibility of prepubescent
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female breasts to cancer induced by ionizing radiation [108]. MNU, a simple
alkylating agent, is radiomimetic [109]. Humans are exposed to alkylating
chemical carcinogens in diet, tobacco products, cosmetics, drugs, and
chemotherapy [110]. The results reported in the current study suggest that the
human NAT1 (an ortholog of rat NAT2) phenotype and prepubescent carcinogen
exposure should be studied as additional factors in human breast cancer
susceptibility.

The role rat NAT2 activity plays in increased tumorigenesis is poorly
understood. Our hypothesis is that a more active rat NAT2 might lower vital
compounds needed for DNA repair to a greater extent than a less active rat
NAT2. Rat NAT2 and human NAT1 are orthologous enzymes that, in addition to
their acetylation capacity, catalyze the hydrolysis of AcCoA to acetate and
coenzyme A in the presence of folate [54, 103]. Thus, rapid rat NAT2 (or more
active human NAT1) can reduce intracellular levels of AcCoA to a greater extent
than slow rat NAT2, affecting crucial pathways supporting DNA repair (e.g.
histone and p53 acetylation). In support of this hypothesis, measurement of
NAT2 activity in rapid acetylator rat tissues showed higher levels of PABA Nacetylation and folate-dependent AcCoA hydrolysis than in slow acetylator rat
tissues. These differences were also reflected in recombinant rapid and slow
acetylator NAT2 expressed in bacteria. As shown with congenic rat tissues and
recombinant NAT2 proteins, REFs isolated from rapid NAT2 rats had a higher
PABA N-acetylation activity level than REFs isolated from the slow NAT2
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congenic rats. Furthermore, rapid NAT2 REFs had lower levels of AcCoA
compared to the slow NAT2 REFs. This observation parallels the findings with
folate-dependent AcCoA hydrolysis, in that rapid acetylator NAT2 is able to
hydrolyze AcCoA at greater rates than slow acetylator NAT2 and thus more likely
to reduce endogenous AcCoA levels.

The study of intracellular AcCoA concentration levels has not been well
characterized after DNA insult. Some studies have shown AcCoA concentrations
control cell growth, cellular autophagy, and histone acetylation [111-113]. Other
studies have shown reduced acetylation of downstream targets if acetyl-CoA
carboxylase, ATP-citrate lyase, or pantothenate kinase are knocked out [113115]. Future studies will further explore human NAT1 activity in relation to
intracellular AcCoA concentrations and associated differences in acetylation
targets. As shown in Chapters 4 and 5, human NAT1 knockdown and knockout
cancer cell lines have elevated AcCoA concentrations compared to their wildtype
counterparts.

Breast cancer is one of the most common types of cancer. It is estimated
that in 2016 breast cancer will be the most diagnosed type of cancer in United
States women, excluding basal and squamous cell skin cancers [116]. It is also
expected that breast cancer will be one of the leading causes of death from
cancer in women, with only lung cancer ranking higher [116]. Breast cancer’s
persistence as one of the most formidable cancers in women illuminates the
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need to understand differences in cancer susceptibility and discover novel
avenues for prevention and treatment. The studies in this chapter primarily focus
on breast cancer. However given ubiquitous expression of NAT1, the findings
here are likely to be observed in other cancer sites such as lung, colon, urinary
bladder, and prostate.
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CHAPTER IV
INHIBITION OF ARYLAMINE N-ACETYLTRANSFERASE 1 REDUCES
ANCHORAGE-INDEPENDENT GROWTH IN HUMAN BREAST CANCER CELL
LINE MDA-MB-231
INTRODUCTION

Arylamine N-acetyltransferase 1 (NAT1) historically is identified as a
phase II drug and carcinogen metabolizing enzyme which catalyzes the transfer
of an acetyl group from acetyl-coenzyme A (AcCoA) to the amine nitrogen of
arylamine and hydrazine compounds. Recently, human NAT1 has been shown to
catalyze hydrolysis of AcCoA in the presence of folate [54, 103].

NAT1 expression is elevated in invasive and lobular breast carcinomas
when compared to normal breast tissue [8]. This overexpression of NAT1 was
confirmed at the mRNA level and by immunohistological analysis in 108 breast
cancer samples that demonstrated a strong association of NAT1 staining and
estrogen receptor-positive tumors [8]. Elevated NAT1 expression in estrogen
receptor-positive tumors has been observed in multiple studies [20, 67]. Also,
elevated NAT1 expression is associated with breast cancer bone metastasis [24,
117]. Adam et al. demonstrated that overexpression of NAT1 in a normal luminal
epithelial-derived cell line conferred enhanced growth properties and etoposide
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resistance compared to control cells that had been transfected with an empty
vector [8]. Subsequent studies demonstrated that a small molecule inhibitor of
NAT1 activity caused decreased cell growth and reduced ability of MDA-MB-231
human breast cancer cells to grow in soft agar [11]. A lentiviral-based NAT1
shRNA, which reduced NAT1 activity by 74%, reduced cell invasion by 50% in
MDA-MB-231 human breast cancer cells [11]. NAT1 activity is cell-cycle phasedependent showing an association between high NAT1 activity and accelerated
progression through the cell cycle in HaCaT keratinocytes [118]. Tiang et al.
showed in the colon cancer cell line HT-29 that RNAi mediated knockdown of
NAT1 by approximately 85% led to increased cell-cell contact inhibition, loss of
cell viability at confluence, and attenuation of anchorage-independent cell growth
[13]. Overall these previous studies have shown a relationship between NAT1
activity and cancer cell proliferation, anchorage-independent growth abilities, and
invasiveness.

Human NAT1 activity is modified by polymorphism, but can also be
regulated by microRNA, epigenetic, and/or translational and post-translational
control features [67-70]. NAT1 transcript levels can be regulated by extracellular
stimuli acting on glucocorticoid or androgen receptors [71, 72]. Exposure to
NAT1 substrates can increase NAT1 degradation, which results in decreased
NAT1 activity [69, 70]. Oxidative stress can reversibly or irreversibly inactivate
NAT1 [119, 120]. NAT1 inhibitors have been reported including cisplatin [121],
curcumin [122, 123], disulfiram [124], and rhodanine derivatives [125, 126]. The
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ability to control the level of NAT1 activity and expression by various means may
reduce cancer growth or metastasis.

To better understand how variation in NAT1 activity can affect cancer cell
growth and invasion properties, we utilized RNAi technology and a small
molecule inhibitor of NAT1 in the human breast cancer cell line MDA-MB-231.
We used the Sure SilencingTM shRNA plasmid described previously [13], and a
rhodanine

derivative

(5E)-[5-(4-hydroxy-3,5-diiodobenzylidene)-2-thioxo-1,3-

thiazolidin-4-one] (5-HDST) similar to the small molecule NAT1 inhibitor reported
previously [126].
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MATERIALS AND METHODS

Cell Line Generation and Culturing Conditions
The breast adenocarcinoma cell line, MDA-MB-231, was purchased from
ATCC (Manassas, Virginia). Cells were cultured in DMEM media, high glucose
with the addition of fetal bovine serum to 10% and glutamine to 2 mM.
SureSilencingTM Predesigned shRNA and NAT1 knockdown shRNA plasmids
were purchased from SA Biosciences. Initial screening found that the NAT1
shRNA Clone 1 reduced NAT1 catalytic activity by 29% while NAT1 shRNA
Clone 3 reduced NAT1 catalytic activity by 50%. Further studies were conducted
with NAT1 shRNA Clone 3 because it was used in previous experiments [10] and
resulted in the greatest reduction in NAT1 expression. The shRNA sequence for
the scrambled shRNA and NAT1 shRNA clone 3 were transferred from the
pGeneclipTM vector to the pcDNA5/FRT vector. The NAT1 overexpression
plasmid NATb/NAT1*4 in pcDNA5/FRT was previously described [127].

A MDA-MB-231 breast cancer cell line with a single FRT site was
constructed using the Flp-In System (Life Technologies, Grand Island, NY) as
described previously [128]. Once an MDA-MB-231 cell line was constructed with
a single FRT site in a transcriptionally active region, we transfected the shRNA
plasmids and the NAT1 overexpression plasmid to deliver the cassettes to the
same genetic location. The pcDNA5/FRT plasmids containing the scrambled
shRNA, NAT1 specific shRNA plasmid or the NAT1 overexpression plasmid

64

NATb/NAT1*4 [127] were co-transfected with pOG44 (Life Technologies), a Flp
recombinase expression plasmid, using Amaxa Cell Line Nucleofector Kit V
(Lonza, Basel, Switzerland) following the manufacturer’s recommendations.
Since the pcDNA5/FRT vector contains a hygromycin resistance cassette, cells
were passaged in complete DMEM containing 500 µg/ml hygromycin to select for
cells with the pcDNA5/FRT plasmid stably integrated into their genomic DNA.
Hygromycin-resistant colonies were selected approximately 2 weeks after
transfection and isolated using cloning cylinders. Unless otherwise stated
experiments using cell lines were performed with cells in log phase of growth.

In summary, the following MDA-MB-231 cell lines were constructed:
1.

Scrambled shRNA cell line stably transfected with scrambled

shRNA as a control cell line to which other cell lines are compared.
2.

NAT1 knockdown cell line stably transfected with NAT1

specific shRNA.
3.

NAT1 overexpression cell line stably transfected with the

NATb/NAT1*4 cassette.

In Vitro and In Situ NAT1 N-acetyltransferase Assays for Cell Lines
In vitro assays using the NAT1 selective substrate para-aminobenzoic
acid (PABA) were conducted and the N-acetyl-PABA product was separated and
quantitated as described [129]. Briefly, cells were scraped from the plate, washed
in 1X phosphate-buffered saline (PBS), and lysed in 20 mM sodium phosphate
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pH 7.4, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.2% triton X-100,, 1 mM
dithiothreitol (DTT), 100 µM phenylmethanesulfonyl fluoride (PMSF), 1 µg/ml
aprotinin, and 2 µM pepstatin A. Cell lysate was centrifuged at 15,000 x g for 10
min and supernatant tested for NAT1 activity. Enzymatic reactions containing 50
µL suitably diluted cell lysate, PABA (300 µM) and acetyl coenzyme A (1 mM)
were incubated at 37°C for 10 min. Reactions were terminated by the addition of
1/10 total reaction volume of 1 M acetic acid and centrifuged at 15,000 X g for 10
min. Three independent measurements (N=3) performed in triplicate were
completed for each cell line.

Measurement of N-acetylation in situ was determined by spiking media
with a known concentration of PABA as described [130]. The cells were
incubated at 37°C for 48 h with media containing 500 µM PABA. Media were
collected and 1/10 total collected media volume of 1 M acetic acid was added.
The acidified media were centrifuged at 15,000 X g for 10 min. There were four
independent measurements (N=4) performed in triplicate for each cell line.

Resulting supernatants from in vitro and in situ NAT1 activity assays was
injected into a reverse phase C18 column (125 mm × 4 mm; 5 µM pore size).
Reactants and products were eluted using a Beckman System Gold high
performance liquid chromatography (HPLC) system. HPLC separation of Nacetyl-PABA was achieved using a gradient of 96:4 sodium perchlorate pH 2.5:
acetonitrile at 280 nm. The data for scrambled shRNA, knockdown and
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overexpression cell lines are represented as mean ± SEM and analyzed
statistically by a one-way ANOVA and Bonferroni post- test.

Endogenous Cellular Acetyl-Coenzyme A (AcCoA) Levels for Cell
Lines
Endogenous AcCoA levels within modified MDA-MB-231 cancer cell lines
(scrambled shRNA, knockdown, and overexpression) were determined by HPLC.
Cell growth conditions were strictly monitored because it was observed that
cellular confluence and period of growth affected the consistency of data
obtained for the endogenous AcCoA concentrations. Cells were plated at 1 x 106
per 10 cm plate (3 plates per N) with fresh complete culturing media with no
selection antibiotic added, and allowed to grow for 72 h. After 72 h, the cells were
70% confluent and collected. Media were aspirated from the plates, and each
plate was washed with 5 ml PBS. Then cells were dissociated from the plate with
0.5 ml trypsin [0.25% (w/v)]. Cells were suspended in 4 ml of diluted complete
media (20% medium and 80% PBS) and counted in 0.5 ml aliquots. In the
subsequent steps all cells and lysates were kept on ice or at 4°C. Collected cells
were centrifuged, supernatant removed, and ice-cold PBS was added. Again,
cells were centrifuged, supernatant removed, suspended in 1 ml of ice-cold PBS,
and transferred to 1.5 ml microcentrifuge tubes. The suspended cells were
collected by centrifugation and the supernatants discarded. Having removed any
residual PBS, the cells were lysed in 100 µL ice-cold 5% 5-sulfosalicylic acid with
a 1 ml BD Insulin Syringe with permanently attached 28 gauge needle (BD
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Franklin Lakes, NJ, USA). The needle selection is important to insure complete
cell lysis without loss of volume or cellular masses within the syringe/needle. The
cellular lysate was then centrifuged at 13,000 x g for 10 min. Supernatant was
filtered through a syringe filter (13 mm, 0.20 µm pore size). Filtrate was collected
and separated on a C18 reverse-phase HPLC column (250 mm × 4 mm; 5 µm
pore size). HPLC separation and quantitation of AcCoA was achieved using a
linear gradient of 100% 55 mM sodium phosphate pH 4.0: 0% methanol to 0% 55
mM sodium phosphate pH 4.0: 100% methanol over 20 min and was quantitated
by absorbance at 260 nm. The data for individual determinations of scrambled
shRNA, knockdown and overexpression cell lines (N= 8, 7, and 7 respectively)
are represented as mean ± SEM, and were analyzed by a one-way ANOVA and
Bonferroni post-test.
Quantitation of NAT1 mRNA Levels
NAT1 mRNA levels were measured as described previously [130]. Briefly,
total RNA was isolated from the constructed MDA-MB-231 cell lines using the
RNeasy

Mini

kit

(Qiagen,

Germantown,

MD)

following

manufacturer’s

instructions. cDNA was made using the High Capacity Reverse Transcriptase kit
(Life Technologies) following manufacturer’s instructions. mRNA was quantitated
via Real-time PCR using Taqman primers and probe (Life Technologies) 5’gaattcaagccaggaagaagca-3’

5’tccaagtccaatttgttcctagact-3’

FAM-5’-

caatctgtcttctggattaa3’-MGB and PCR conditions suggested by the manufacturer.
The data for scrambled shRNA, knockdown and overexpression cell lines are
represented as mean ± SEM from three separate determinations performed in

68

triplicate (N=3), and were analyzed statistically by a one-way ANOVA and
Bonferroni post-test.
Determination of Doubling Time of Cell Lines
Twenty-five thousand cells were plated in triplicate in 6-well plates and
allowed to grow for 5 consecutive days. Cells were plated on day 1 and allowed
to equilibrate for 24 h before making the first count on day 2 followed by counts
on days 3, 4, 5 and 6 using a cell counter. A cell doubling rate was calculated for
each day using Equation 1 (shown below) and then rates were averaged over the
5 day time period to get a final cell doubling rate.
Equation 1: Cell Doubling Rate = 1/(((log b − log (a))×3.32)/(t ! − t ! ))
In the equation, b = cell number on day n, a = cell number on day n-1, t ! =
hours passed since plating when cells were counted on day n, and t ! = hours
passed since plating when cells were counted on day n-1. This assay was
performed in triplicate for each cell line (N=3). The data for the cell lines are
represented as mean ± SEM from three separate determinations performed in
triplicate, and were analyzed statistically by a one-way ANOVA and Bonferroni
post-test.

Measuring the Effect of a Small Molecule Inhibitor on In Situ NAT1
Activity and Cell Growth
The ability of the small molecule inhibitor (5E)-[5-(4-hydroxy-3,5diiodobenzylidene)-2-thioxo-1,3-thiazolidin-4-one] (5-HDST, CAS# 336171-85-8)
(Ryan Scientific, Mount Pleasant, SC) to inhibit NAT1 activity was measured in
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situ and its effects on cell growth measured as a percentage of untreated cells.
Scrambled shRNA MDA-MB-231 cells were incubated with a single dose of 5HDST (ranging from 0-87.5 µM) for up to 6 days. Briefly, all cells were plated on
day 0 and the varying concentrations of 5-HDST were added to the respective
cells on day 1. Cells were plated in 12-well plates so that every successive day
would have roughly the same number of cells to enable accurate measurement
of PABA N-acetylation in situ and cell number. PABA (10 µM) was added to the
media and incubated with the cells and 5-HDST for 24 h prior to measurements.
After 24 h, media were removed from the cells and amounts of PABA and Nacetyl-PABA were measured by HPLC as described above. Cells were washed
once with 1X PBS, scraped off the plate and counted using a cell counter. Three
separate determinations performed in triplicate for PABA N-acetylation and cell
number were carried out every 24 h for 6 days (N=3). The in situ NAT1 data,
represented as means ± SEM, were analyzed statistically by a one-way ANOVA
and Bonferroni post-test on day 6. The cell number data, represented as means
± SEM, were analyzed statistically by a two-way ANOVA and Bonferroni posttest.

Anchorage-Dependent and Anchorage-Independent Growth Assays
Anchorage-dependent growth assays were performed by plating cells (300
cells/well) in triplicate in 6-well plates and allowing them to grow for 2 weeks
(N=3). For small molecule NAT1 inhibitor assays, 5-HDST (ranging from 0 to
87.5 µM) was added to triplicate wells at the time of plating (N=3). Colonies were
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counted following staining with crystal violet. The data are represented as means
± SEM from three separate determinations performed in triplicate and were
analyzed statistically by a one-way ANOVA and Bonferroni post-test.
The anchorage-independent growth assays were performed by plating the
cells in low-melting temperature agarose. The cells were grown in normal growth
media where the bottom layer was 1.5 ml (noble agar, 0.5%) and the top layer
was 1.5 ml (low-melting temperature agarose, 0.3%), so the total volume was 3
ml in each well of a 6 well plate. Cells (6000 cells/well) were plated in triplicate in
6-well plates and grown for 2 weeks. Colonies were counted following staining
with crystal violet. For the anchorage-independent growth assay investigating
effect of the small molecule NAT1 inhibitor, 5-HDST (ranging from 0 to 87.5 µM)
was added at the time of plating of the cells. Three separate determinations
performed in triplicate were completed for each assay (N=3). The data are
represented as means ± SEM and were analyzed statistically by a one-way
ANOVA and Bonferroni post- test.

Transwell Assays to Assess Relative Invasive Ability
Transwell assays were performed by depositing 1 X 105 cells in 100 µL of
DMEM containing 0.2% FBS in the top chamber of the transwell and 600 µL of
complete media in the bottom chamber. 5-HDST (ranging from 0 to 100 µM) was
added to media on both sides of the membrane. Cells were allowed to invade
across a membrane of Matrigel (Life Technologies). After 24 h, cells on the top
side of the membrane were removed with a sterile cotton swab. Cells that
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invaded across the membrane were quantified using the Alamar Blue cell
quantitation assay. Three separate determinations performed in triplicate were
made (N=3). The data are represented as means ± SEM, and were analyzed
statistically by one-way ANOVA and Bonferroni post-test.
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RESULTS

NAT1 Catalytic Activity, Endogenous AcCoA Levels, and mRNA
Expression
The stable partial knockdown of NAT1 reduced in vitro PABA NAT1 Nacetylation to 61% of the scrambled shRNA cell line (figure 4.1A) and in situ
PABA N-acetylation to 62% of the scrambled shRNA cell line (figure 4.1B).
Stable overexpression of NAT1 increased the N-acetylation of PABA in vitro and
in situ by 12-and 11-fold, respectively, compared to the scrambled shRNA cell
line (figure 4.1 A&B). The partial knockdown of NAT1 in NAT1 shRNA
knockdown MDA-MB-231 breast cancer cells increased endogenous AcCoA
levels about 35% compared to the scrambled shRNA cell line (p<0.005) (figure
4.1C). Endogenous AcCoA levels in the NAT1 overexpression MDA-MB-231 cell
line did not differ significantly (p>0.05) compared to the scrambled shRNA cell
line but were significantly below the AcCoA levels of the partial NAT1 knockdown
cell line (p<0.05) (figure 4.1C). NAT1 mRNA expression in the stable knockdown
was 47% of the scrambled shRNA cell line, and was 31-fold higher than the
scrambled shRNA cell line in the stable NAT1 overexpression cell line (figure
4.1D).
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FIGURE 4.1

Figure 4.1. NAT1 catalytic activity and mRNA expression in stably modified
MDA-MB-231 cell lines. Each bar illustrates mean ± SEM. The in vitro PABA Nacetylation activity (A) in cell line lysates (N=3). The in situ PABA N-acetylation
(B) in cell lines cultured in PABA spiked media (N=4). The endogenous AcCoA
levels (C) for scrambled shRNA (N=8), NAT1 shRNA knockdown (N=7), and
NAT1 overexpression (N= 7). NAT1 mRNA levels (D) in cell lines normalized to
scrambled shRNA cell line (N=3). Differences between cell lines were
significantly different (* p≤ 0.05; *** p≤ 0.001) following one-way ANOVA with a
Bonferroni post-test.
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Cell Growth
The doubling times for the scrambled shRNA cell line, NAT1 knockdown
cell line and NAT1 overexpression cell line were 27.4, 27.2 and 23.4 hours
respectively (figure 4.2A). Neither the knockdown nor overexpression of NAT1
significantly (p=0.26) affected the doubling time compared to the scrambled cell
line.

Anchorage-Dependent Cell Growth, Anchorage-Independent Cell
Growth, and Relative Invasive Ability
Neither the knockdown nor overexpression of NAT1 significantly affected
anchorage-dependent growth (figure 4.2B). However, the knockdown of NAT1
caused a significant 7-fold decrease (p<0.0001) in anchorage-independent
growth, whereas the overexpression of NAT1 had no significant effect (figure
4.2C). Neither knockdown of NAT1 with shRNA nor overexpression of NAT1 had
a significant effect on relative invasive ability (figure 4.2D).
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FIGURE 4.2

Figure 4.2. Cell growth properties in shRNA NAT1 knockdown and
overexpression stably modified MDA-MB-231 cell lines. Each bar illustrates
mean ± SEM. Cell doubling times (A) in the scrambled shRNA, NAT1 knockdown
and NAT1 overexpression cell lines did not differ significantly following one-way
ANOVA (p>0.05) (N=3). The anchorage-dependent growth (B) did not differ
significantly among the scrambled shRNA, NAT1 knockdown and NAT1
overexpression cell lines following one-way ANOVA (p>0.05) (N=3). The NAT1
knockdown cell line formed significantly less anchorage-independent colonies (C)
compared to scrambled shRNA and NAT1 overexpressing cell lines following
one-way ANOVA followed by a Bonferroni post-test (*** p≤ 0.001) (N=3). No
significant differences in relative invasion ability (D) among the scrambled
shRNA, NAT1 knockdown and NAT1 overexpression cell lines were observed
following one-way ANOVA (p>0.05) (N=3).
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Effects of Small Molecule NAT1 Inhibitor on MDA-MB-231 Breast
Cancer Cells
To demonstrate that the effects of NAT1 knockdown on cell growth and
invasion ability were due to reduced NAT1 activity, we tested the effects of a
small molecule inhibitor of NAT1 that does not depend on decreased NAT1
expression for reduced NAT1 catalytic activity.

N-acetylation In Situ
5-HDST (figure 4.3A) reduced PABA N-acetylation in situ in a
concentration-dependent manner (p<0.0001)(figure 4.3B). A single dose of 5HDST reduced PABA N-acetylation in situ for at least 6-days (figure 4.3B). The
IC50 for inhibition of PABA N-acetylation in situ on day 6 was 47.6 ± 1.07 µM
(figure 4.3C).

Cell Growth
Cells exposed to concentrations of 5-HDST ranging from 0 to 50 µM over
a period of up to 6 days produced no significant effects on cell growth (figure
4.4A). Concentrations of 5-HDST greater than 50 µM caused a concentrationand time-dependent decrease in cell growth (p<0.0001) (figure 4.4A).
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Anchorage-Dependent and -Independent Cell Growth, and Relative
Invasive Ability
Incubation with 5-HDST reduced anchorage-dependent cell growth, but
the effect was marginal below 50 µM (figure 4.4B). Incubation with 5-HDST
markedly reduced anchorage-independent cell growth at 12.5 µM (figure 4.4C).
Incubation with 5-HDST had no effect on relative invasion ability until
concentrations of 5-HDST exceeded 75 µM (p<0.05)(figure 4.4D).
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FIGURE 4.3

Figure 4.3. Effects of a small molecular inhibitor (5-HDST) on NAT1 activity.
Chemical structure of 5-HDST (A). The percentage of NAT1 activity remaining
after incubation with 0 to 87.5 µM 5-HDST (B) for 1-6 days (N=3). 5-HSDT
inhibition of NAT1 activity curve (C) used to calculate the IC50 for 5-HSDT
inhibition of NAT1 at day 6 (N=3). The IC50 was 47.6 ± 1.07 µM.
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FIGURE 4.4

Figure 4.4. Cell growth properties of MDA-MB-231 cells incubated with 5-HDST.
Bars/symbols represent means ± SEM from three separate determinations
performed in triplicate (N=3). Cell number (percent of vehicle) measured after
incubation (1-6 days) with 5-HDST (A). Anchorage-dependent colongy formation
following incubation with 5-HDST after 14 days (B). Anchorage-independent
colony formation following incubation with 5-HDST after 14 days (C). Transwell
assays to measure migratory ability of scrambled shRNA cell line incubated with
5-HDST (D). One-way ANOVA was conducted to compare relative invasion
ability between groups (p<0.05). The scrambled shRNA cell line incubated with
100 µM 5-HDST had significantly (p<0.05) less invasion ability compared to
scrambled shRNA cell line incubated with vehicle following one-way ANOVA and
Bonferroni post-test (p<0.05).
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DISCUSSION

Understanding how heterogeneity in gene expression affects cancer cell
growth characteristics is very important. As outlined in the introduction,
differences in human NAT1 expression have been reported to alter cancer cell
growth properties. The goal of this study was to replicate previous findings and
investigate further whether differences in human NAT1 expression affect breast
cancer cell growth and metastatic properties. We knocked-down and
overexpressed NAT1 using a FRT system (Life Technologies), which facilitates
investigations of decreased or increased NAT1 expression independent of
chromosomal position effects because all the expression cassettes were inserted
into the same genomic location.

NAT1 knockdown using shRNA resulted in approximately 39% reduction
in NAT1 in vitro catalytic activity, a comparable 35% increase in cellular AcCoA
levels, and a 7-fold decrease in anchorage-independent growth compared to the
scrambled shRNA cell line. However the NAT1 shRNA knockdown did not yield
significant changes (p>0.05) in cell doubling time, anchorage-dependent growth
or relative invasion ability. Previous studies, using the same NAT1 shRNA
knockdown plasmid in a colon adenocarcinoma cell line achieved an 80-90%
knockdown of NAT1 [13] with significant changes in cell growth and invasion but
only a 15% reduction in anchorage-independent cell growth. The differences
observed between the present study and the previous NAT1 knockdown study
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[13] could be due to the different cell line used or the level of NAT1 knockdown. It
is possible there is a threshold knockdown of NAT1 required to observe effects
on cell growth and cell invasion that is tissue or cell-type specific.

Despite a 12-fold overexpression of NAT1 in vitro activity, significant
(p>0.05) changes in endogenous AcCoA levels, cell doubling time, anchoragedependent growth, anchorage-independent cell growth, or relative invasion ability
were not observed. In contrast a previous study using HB4a cells reported that
NAT1 overexpression resulted in enhanced growth properties [8]. The MDA-MB231 cells used in the present study are a claudin-low, triple-negative breast
cancer cell line whereas the HB4a cell line is derived from normal luminal
mammary epithelial cells. Thus, the lack of differences between scramble shRNA
and NAT1 overexpression MDA-MB-231 cell lines may be a result of the cell line
utilized.

Recent reports that NAT1 catalyzes the hydrolysis of AcCoA in the
presence of folate suggests that NAT1 may affect endogenous levels of AcCoA
[54]. Consistent with this concept, we found that partial NAT1 knockdown by 39%
elevated endogenous AcCoA levels by 35% (figure 4.1C). Although this finding is
consistent with AcCoA hydrolysis catalyzed by NAT1, it does not provide
evidence this is the primary or sole mechanism for the elevation of AcCoA. Rat
embryonic fibroblasts from rapid acetylator congenic rats have lower levels of
AcCoA than rat embryonic fibroblasts derived from slow acetylator congenic rats
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[65]. Thus while a direct connection for physiological differences in AcCoA levels
cannot be drawn to NAT1 AcCoA hydrolysis, accumulating data suggest that
NAT1 may influence endogenous AcCoA levels. Differences in AcCoA levels
could provide an explanation for differences in metabolites of fatty acid synthesis
and amino acids [131]. The effects of NAT1 knockdown on anchorageindependent cell growth and endogenous AcCoA levels may provide insight into
why congenic rapid NAT2 (ortholog to human NAT1) activity rats developed more
mammary tumors than congenic slow NAT2 rats following administration of
mammary carcinogens that are not metabolized by rat NAT2 [65].

A second objective of this study was to compare inhibition of NAT1 via a
small molecule inhibitor to NAT1 knockdown using shRNA. We selected a small
molecule inhibitor (5-HDST) similar to that identified and characterized previously
[126]. The scrambled shRNA cell line was utilized as the control in both the small
molecular inhibitor and shRNA knockdown experiments to facilitate this
comparison.

5-HDST decreased the ability of the breast cancer cell line to N-acetylate
PABA in situ. Cell growth was reduced in a concentration dependent manner
above 50 µM (figure 4.4A). Our experiments did not provide evidence that the
reduction in cell growth was solely caused by NAT1 inhibition; but did show that
the concentration-dependent effects on NAT1 catalytic activity and cell growth
were similar in trend on day six. In the scrambled shRNA cell line incubated with
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5-HDST, we observed a decrease in both anchorage-dependent and anchorageindependent cell growth. It is possible that the reduction in anchorage-dependent
growth reflects cellular toxicity of the small molecule inhibitor. The reduction in
anchorage-independent growth reflects a combination of cellular toxicity and
ability of the 5-HDST to inhibit NAT1 and thereby reduce anchorage-independent
growth in the breast cancer cell line MDA-MB-231.

The IC50 value for the small molecule inhibitor 5-HDST was 47.6 ± 1.07
µM by in situ PABA N-acetylation inhibition assay. A previous study determined
an

IC50

value

of

101

±

11

µM

for

(Z)-5-(2-hydroxybenzylidene)-2-

thioxothiazolidin-4-one (Rhod-o-hp), which is structurally similar to 5-HDST, by
an in situ PABA N-acetylation inhibition assay [11]. The IC50 for 5-HDST also was
lower than the IC50 for both folate and MTX (76.9 ± 1.05 µM and 127 ± 1.06 µM,
respectively). Thus, 5-HDST was a more potent NAT1 inhibitor than folate, MTX,
and Rhod-o-hp.

Previous studies using a different small molecule inhibitor of NAT1 in a
different cell line reduced cell growth, relative invasion ability and anchorageindependent cell growth similar to those observed with NAT1 knockdown using
shRNA [11, 13]. We assessed relative invasion ability using a transwell assay
and observed no change in the scrambled shRNA cell line treated with the small
molecule

inhibitor

5-HDST

until

the
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concentration

exceeded

75

µM.

Concentrations of 5-HDST as high as 87.5 µM showed no effects on cell viability
at the 24 hr time point.

In summary, our findings compliment but do not fully replicate previous
reports regarding the effect of NAT1 knockdown on cancer cell properties. In our
studies, approximately 40% inhibition of NAT1-catalyzed N-acetylation in the
MDA-MB-231 breast cancer cell line by either shRNA knockdown or 5-HDST
resulted in a significant decrease in anchorage-independent growth without
affecting overall cell growth and relative invasion ability. NAT1 shRNA partial
knockdown increased endogenous AcCoA levels 35% compared to the
scrambled shRNA and NAT1 overexpression. The results of our study strongly
confirm that further studies are needed. Rather than carrying out more extensive
mechanistic studies on a cell line with a very modest NAT1 knock down (39%),
we are now utilizing a new model system, CRISPR/Cas9, that makes permanent
deletions at the NAT1 gene open reading frame causing 100% knockout of
NAT1. Use of this model, as discussed in the following chapter, has confirmed
the findings of this study that further suggests that human NAT1 could serve as a
target for the prevention and/or treatment of breast cancer.
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CHAPTER V
CRISPR/CAS9 MEDIATED KNOCK OUT OF ARYLAMINE NACETYLTRANSFERASE 1 (NAT1) IN HUMAN ADENOCARCINOMA BREAST
CANCER CELL LINES
INTRODUCTION

Modifications of human NAT1 expression within a human cancer cell line
have mostly either been to overexpress or to knockdown expression partially [8,
11, 13]. In order to obtain a complete knock out of cellular NAT1 activity CRISPR/
Cas9 was utilized to alter the genomic sequence of NAT1 within a cell. There are
many benefits and some disadvantages in using this rapidly adopted
experimental technique, however the end result is a novel genomic knockout for
NAT1.

An initial publication from Ishino et al. in 1987 detailed an observation of a
cluster of repeat sequences arranged with a spacer sequence, but stated the
biological significance was unknown [132]. This sequence, with an unknown
significance, would later be known as Clustered Regularly Interspaced
Palindromic Repeats (CRISPR). In 2005, the spacer sequences were determined
to be foreign in origin, and considered to play a role in the organism’s adaptive
defense system [133-135]. A major requirement was a group of CRISPR-
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associated (Cas) genes/enzymes. The Cas9 gene encodes an RNA guided
nuclease that targets DNA introduced from phage infections.

Years of work from several groups resulted in understanding the
mechanism by which the adaptive immunity works, and the functional ability of
the system within mammalian cells. The mechanism for CRISPR/Cas9 activity
involves a pair of RNAs that work together to target a specific sequence and a
large multi-subunit endonuclease complex (Cas9) to cleave the non-host DNA.
The two RNAs are: “crRNA” that is a processed spacer/repeat sequence and
“tracrRNA” that shares a complementary region with “crRNA”[136, 137]. When
these separate RNA sequences bind together they are able to guide Cas9 to a
specific target site encoded by the spacer sequence. Beside the complementary
sequence to spacer sequence the DNA sequence must have a protospacer
adjacent motif (PAM) follow the target site for the cleavage of DNA. The two RNA
sequences “crRNA” and “tracrRNA” were simplified in 2012 by Jinek et al. when
they showed that a chimeric transcript, was able to take Cas9 to the target
sequence and cleave the DNA [138].

The Cas9/guide RNA (gRNA) complex interacts with complementary
genomic DNA sequence, and this interaction causes the Cas9 to engage its twonuclease domains. The nuclease domains form a double strand break (DSB)
about 3 nucleotides before the PAM site. The PAM site commonly used is ‘NGG’
from Streptococcus pyogenes Cas9 (SpCas9). This PAM site, which occurs
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frequently in the genome, generally imposes only minimal constraints on target
site selection and gRNA design.

The cell’s DNA repair pathways repair DNA DSB cleavage resulting from
Cas9. Those DNA repair pathways are either homologous recombination
(homology directed-repair (HDR)) or non-homologous end joining (NHEJ). HDR
repairs a DSB precisely with the aid of a DNA template. While the cell is in cell
cycle the sister chromatid would serve as the template, however an exogenous
DNA sequence can allow for a new sequence to be introduced into the genomic
DNA. The NHEJ is the main DSB repair pathway within most mammalian cells
with the pathway being active in all phases of the cell cycle. As opposed to HDR,
NHEJ does not require a homologous DNA sequence to direct the repair of the
DSB, and this difference often results in genomic insertions/deletions, termed
indels, after NHEJ repair of DSB. Indels range in size, and if indels occur within
the protein-coding region of a gene then a frameshift mutation can result. A
frameshift mutation can produce an amino acid sequence that is terminated
early. This type of frameshift mutation can effectively produce a knocking out of
the gene.

To summarize, CRISPR/Cas9 system is composed of three parts. The first
is the gRNA with a spacer sequence (like from a “crRNA”) to target a DNA
sequence and a sequence to complex with the Cas9 (like from a “tracrRNA”).
Cas9 when guided by the gRNA uses the two nuclease-domains to form a DSB
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just before the PAM site. The PAM site is required for the CRISPR/Cas9 system
to cleave the targeted DNA sequence. The relative simplicity of the mechanism
explains the wide and rapid adoption of the technique.

The CRISPR/Cas9 system has some disadvantages that are often under
represented. The precision of the Cas9 complex (in particular SpCas9) has been
reported several times to cleave the genomic DNA in unintended sites [139-144].
Some gRNAs can act on more than 100 off-target sites [145]. These off target
breaks have the potential to result in multiple mutations and genomic
rearrangement, which could alter cellular properties different from that of the
desired target of the Cas9 complex.

While groups around the world work to improve the precision of individual
Cas9 complexes, the present study uses two separate gRNAs that target
separate sequences within the early portion of the NAT1 gene. If an off-target
event takes place with one gRNA then it will not likely happen in the other gRNA.
In this scheme for a phenotype to be related to NAT1 knockout both gRNAs must
display the same phenotype.

This study utilizes two human breast cancer cell lines MDA-MB-231 and
MCF7. The cell lines originate from separate pleural effusions of different
malignant breast cancer patients, and have been used for decades in breast
cancer research. Claudin-low MDA-MB-231 are estrogen receptor negative,
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progesterone receptor negative, and HER2 negative. MDA-MB-231 cells also
have little to no cohesion, and are stellate in structure. Luminal A MCF-7 cells are
estrogen receptor positive, progesterone receptor positive, and HER2 negative.
MCF7 cell line can form tightly cohesive structures, which show more cell-cell
adhesions. In using two different cell lines, we are trying to establish if the knock
out of NAT1 will show similar effects across different breast cancer
classifications.

To understand better how knocking out NAT1 activity can affect cancer
cell growth and invasion properties, this study utilized CRISPR/Cas9 technique
with two unique gRNA sequences for the early portion of the 5’ region of the
open reading frame for NAT1 gene in human breast cancer cell lines MDA-MB231 and MCF7.
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MATERIALS AND METHODS

Cell Line Generation and Culturing Conditions
The cell lines utilized within this study were the MDA-MB-231 and MCF7
breast adenocarcinoma cell lines obtained from ATCC (Manassas, Virginia).
Cells were cultured in DMEM media, high glucose with the addition of fetal
bovine serum to 10% and glutamine to 2 mM. The cell lines were grown in a
humidified incubator set at 37 °C with 5% CO2. Horizon Discovery Group
(Cambridge CB525 9TL, United Kingdom) designed the 5 different gRNAs for
NAT1 and DNA2.0 Inc (Menio Park, CA) cloned the gRNAs into a Cas9
expressing vector expressing a dasher-GFP tag. Separately, each of the 5 gRNA
/Cas9 vectors were transiently transfected in MDA-MB-231 cells using the
Amaxa Nucleofector II (Lonza, Allendale, NJ). Forty-eight hours after transfection
cells were harvested and DNA isolated. We used the Transgenomic (Omaha,
NE) SURVEYOR Mutation Detection Kit to determine the effectiveness of each
gRNA’s ability to cut the genomic and induce DNA strand breaks effectively. The
gRNAs #2 and #5 were the most effective at inducing DNA strand breaks, and
where chosen to separately knockout the function of NAT1 in the following
studies.
MDA-MB-231 cells were transfected with either #2 or #5 gRNA /Cas9
vectors as above, and 48 hours after transfection cells were sorted for GFP
fluorescence. MCF7 was transfected with either #2 or #5 gRNA /Cas9 with
Lipofectamine

3000

(Invitrogen,

California,
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USA),

and

48

hours

after

transfections cells were sorted for GFP fluorescence. The fluorescent positive
cells were collected, and plated at a very dilute cell concentration so that
individual unique clones could be isolated. After several weeks individual cells
grew into large enough colonies to utilize cloning cylinders to trypsin cells off the
plate and transfer to a 96-well culture plate. Clones were passaged into a 10 cm
dish and tested for NAT1 activity. A low number of clones with knockout of NAT1
activity were selected for further characterization. Knockout clones for NAT1
activity were screened by sequencing of the NAT1 open reading frame to find
clones that had deleted/inserted nucleotides that resulted in a frame-shift
mutation and early protein termination signals resulting in nonfunctional NAT1.
The individual cloned knockout cell lines representing the knockout of NAT1
activity for either gRNA #2 or #5 were chosen based upon the measurement of
NAT1 acetyltransferase activity and genomic sequence.

Sequencing of the NAT1 Gene in the gRNAs #2 and #5 Knockout
Clones
Genomic DNA was isolated from both MDA-MB-231 and MCF7 cloned
knockout cell lines. The NAT1 open reading frame was TOPO cloned using
pcDNA™ 3.1/V5-His TOPO® TA Expression Kit (Invitrogen, California, USA)
following manufacture’s recommendations. The TOPO Cloning reaction for the
individual cell lines was transformed into One Shot TOP10 Chemically
Competent E. coli. For each NAT1 knockout cell line, five transformed E. coli
colonies were selected and grown overnight. Cultures of bacteria were then
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harvested for plasmid purification. Purified plasmids and primers were sent for
DNA sequencing (Eurofins, Louisville, KY, USA). Sequence data was analyzed
and aligned with SeqMan Pro™ (Version 12.0, DNASTAR, Madison, WI.)

In Vitro and In Situ NAT1 N-acetyltransferase Assays
In vitro assays using the NAT1 selective substrate para-aminobenzoic
acid (PABA) were conducted and acetylated products were separated and
quantitated as described [129]. Briefly, cells were scraped from the plate, washed
in 1X phosphate-buffered saline (PBS), and lysed in 20 mM sodium phosphate
pH 7.4, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.2% triton X-100,, 1 mM
dithiothreitol (DTT), 100 µM phenylmethanesulfonyl fluoride (PMSF), 1 µg/ml
aprotinin, and 2 µM pepstatin A. Cell lysate was centrifuged at 15,000 x g for 10
min and supernatant tested for NAT1 activity. Enzymatic reactions containing 50
µL suitably diluted cell lysate, PABA (300 µM) and acetyl coenzyme A (1 mM)
were incubated at 37°C for 10 min. Reactions were terminated by the addition of
1/10 total reaction volume of 1 M acetic acid and centrifuged at 15,000 X g for 10
min. Three independent measurements (N=3) performed in triplicate were
completed for each cell line.

Measurement of N-acetylation in situ was determined by spiking media
with a known concentration of PABA as described [130]. The cells were
incubated at 37°C for 48 h with media containing 500 µM PABA. Media were
collected, and 1/10 total collected media volume of 1 M acetic acid was added.
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Then the acidified media were centrifuged at 15,000 X g for 10 min. There were
three independent measurements (N=3) for MDA-MB-231 and four independent
measurements (N=4) for MCF7 all performed in triplicate.

Resulting supernatants from in vitro and in situ NAT1 activity assays were
injected into a reverse phase C18 column (125 mm × 4 mm; 5 µM pore size).
Reactants and products were eluted using a Beckman System Gold high
performance liquid chromatography (HPLC) system. HPLC separation of Nacetyl-PABA was achieved using a gradient of 96:4 sodium perchlorate pH 2.5:
acetonitrile at 280 nm. The data for scrambled shRNA, knockdown and
overexpression cell lines are represented as mean ± SEM and analyzed
statistically by a one-way ANOVA and Bonferroni post hoc test.

Endogenous Acetyl-Coenzyme A (AcCoA) Levels
Endogenous AcCoA levels within modified MDA-MB-231 and MCF7
cancer cell lines were determined by HPLC-UV. Cell growth conditions were
strictly monitored because it was observed that cellular confluence and period of
growth affected the consistency of data obtained for the endogenous AcCoA
concentrations. Cells were plated at 1 x 106 per 10 cm plate (3 plates per N) with
fresh complete culturing media with no selection antibiotic added, and allowed to
grow for 72 h. After 72 h, the cells were 70% confluent and collected. Media were
aspirated from the plates, and each plate was washed with 5 ml PBS. Then cells
were dissociated from the plate with 0.5 ml trypsin [0.25% (w/v)]. Cells were
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suspended in 4 ml of diluted complete media (20% medium and 80% PBS) and
counted in 0.5 ml aliquots. In the subsequent steps all cells and lysates were
kept on ice or at 4°C. Collected cells were centrifuged, supernatant removed, and
ice-cold PBS was added. Again, cells were centrifuged, supernatant removed,
suspended in 1 ml of ice-cold PBS, and transferred to 1.5 ml microcentrifuge
tubes. The suspended cells were collected by centrifugation and the
supernatants discarded. Having removed any residual PBS, the cells were lysed
in 100 µL ice-cold 5% 5-sulfosalicylic acid with a 1 ml BD Insulin Syringe with
permanently attached 28 gauge needle (BD Franklin Lakes, NJ, USA). The
needle selection is important to insure complete cell lysis without loss of volume
or cellular masses within the syringe/needle. The cellular lysate was then
centrifuged at 13,000 x g for 10 min. Supernatant was filtered through a syringe
filter (13 mm, 0.20 µm pore size). Filtrate was collected and separated on a C18
reverse-phase HPLC column (250 mm × 4 mm; 5 µm pore size). HPLC
separation and quantitation of AcCoA was achieved using a linear gradient of
100% 55 mM sodium phosphate pH 4.0: 0% methanol to 0% 55 mM sodium
phosphate pH 4.0: 100% methanol over 20 min and was quantitated by
absorbance at 260 nm. The data for individual determinations of CRISPR clones
are represented as mean ± SEM with eight independent measurements (N=8) for
MDA-MB-231 and twelve independent measurements (N=12) for MCF7. Data
were analyzed by a one-way ANOVA and Bonferroni post test.
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Determination of Doubling Time
Twenty-five thousand cells were plated in triplicate in 6-well plates and
allowed to grow for 5 consecutive days. Cells were plated on day 1 and allowed
to equilibrate for 24 h before making the first count on day 2 followed by counts
on days 3, 4, 5 and 6 using a cell counter. A cell doubling rate was calculated for
each day using Equation 1 (shown below) and then rates were averaged over the
5 day time period to get a final cell doubling rate.

Equation 1: Cell Doubling Rate = 1/(((log b − log (a))×3.32)/(t ! − t ! ))

In the equation, b = cell number on day n, a = cell number on day n-1, t ! =
hours passed since plating when cells were counted on day n, and t ! = hours
passed since plating when cells were counted on day n-1. This assay was
performed in triplicate for each cell line (N=3). The data for the cell lines are
represented as mean ± SEM from three separate determinations performed in
triplicate, and were analyzed statistically by a one-way ANOVA and Bonferroni
post hoc test.

Anchorage-Dependent and Anchorage-Independent Growth Assay
Anchorage-dependent growth assays were performed by plating cells (300
cells/well) in triplicate in 6-well plates and allowing them to grow for 2 weeks.
Colonies were counted following staining with crystal violet. The data are
represented as means ± SEM from six independent measurements (N=6) for
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MDA-MB-231 and seven independent measurements (N=7) for MCF7 all
performed in triplicate, and were analyzed statistically by a one-way ANOVA and
Bonferroni post test.

The anchorage-independent growth assays were performed by plating the
cells in low-melting temperature agarose. The cells were grown in normal growth
media where the bottom layer was 1.5 ml (noble agar, 0.5%) and the top layer
was 1.5ml (low-melting temperature agarose, 0.3%), so the total volume was 3
ml in each well of a 6 well plate. Cells (6000 cells/well) were plated in triplicate in
6-well plates and grown for 2 weeks. Colonies were counted following staining
with crystal violet. Three independent measurements (N=3) for MDA-MB-231 and
four independent measurements (N=4) for MCF7 performed in triplicate were
completed for each assay. The data are represented as means ± SEM and were
analyzed statistically by a one-way ANOVA and Bonferroni post hoc test.

Anoikis Assay and Hanging Drop Assay
The anoikis assay required the wells of 96-well plates to be coated with a
polymer known as poly-HEMA (Sigma). The poly-HEMA powder was dissolved in
95% ethanol at a concentration of 50 mg/ml to generate a stock solution. The
working solution for poly-HEMA was made by diluting the 50 mg/ml stock at a
1:10 ratio in 100% ethanol to a final concentration of 5.0 mg/ml. The wells of 96well plates were coated with two layers of poly-HEMA, and the plates were dried
overnight between each coating. Each experimental well, with or without poly-
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HEMA coating, was given 4.0 x 103 MDA-MB-231 cells in 100 µL of complete
media. Controls wells with or without poly-HEMA coating had no cells included.
Cells were incubated overnight before recording the 0 hour reading. Number of
cells within each well was quantified by AlmarBlue® cell quantitation assay.
Briefly, each well received 10 µL of AlmarBlue® and incubated for an additional 3
hours, and then fluorescence read on a plate reader for 0 to 96 hours measured
at 24 hour time points. Three separate determinations performed in triplicate
were made (N=3). The data are represented as means ± SEM, and were
analyzed statistically by two-way ANOVA and Bonferroni post hoc test.

Hanging drop assay was performed by suspending 12.5 µl complete
culture media droplets containing 5000 MDA-MB-231 cells onto the inner surface
of the lid of a 10 cm culture dish. Ten ml of PBS was placed into the dish to
prevent evaporation of the hanging droplets. Cells within four individual droplets
were counted by trypan blue exclusion for the number of dead cells compared to
the number of live cells per individual determination (N). The time points were 24,
48 and 72 hours. Seven separate determinations performed in quadruplicate
were made (N=7). The data are represented as means ± SEM, and were
analyzed statistically by two-way ANOVA and Bonferroni post hoc test.

Transwell Assays to Assess Relative Invasive Ability
The inserts of permeable Transwell wells were either coated with or
without 100 µl of 0.5 mg/ml Matrigel (Life Technologies), and the Matrigel was
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allowed to solidify for 2 h at 37°C. Upper chambers of the transwells were
seeded with either 2.5 X 104 or 5 X 104 MDA-MB-231 cells in 100 µl of media
containing 0% FBS. The bottom chamber of the transwells contained 600 µL of
complete media. Cells were incubated at 37°C with 5% CO2 and allowed to
invade across the Matrigel for 24 h. After incubation, cells on the topside of the
transwell membrane were removed with a sterile cotton swab. Cells that invaded
across the membrane were counted utilizing crystal violet staining. Four separate
determinations performed in duplicate were made (N=4). The data are
represented as means ± SEM, and were analyzed statistically by one-way
ANOVA and Bonferroni post hoc test.

In Vitro Wound-Closure Assay
The method is based on the previous protocol published by Peterson et al.
in 2014 [146]. Silicone elastomer base (Sylgard 184 Elastomer; Dow Corning,
Midland, MI, USA) was prepared per manufacturer's directions. A 2-mm biopsy
punch was used to create five silicone plugs/well. The plugs were placed directly
on the bottom of a 6-well plate. MDA-MB-231 and gRNA #2 and #5 clones were
plated at a concentration of 600,000 cells/well and incubated for 48 hours so that
the cells are confluent around the plugs. Plugs were removed to create a 2-mm
diameter area and the remaining cells were washed twice with PBS. The cell free
area created by the plug was photographed each day. The area free of cells was
quantified for each time point using ImageJ software (http://imagej.nih.gov/ij/;
provided in the public domain by the National Institutes of Health (Bethesda, MD,
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USA) [147]. Data were plotted as the percentage of the initial area that was
covered (wound closure) for each time point. Each data point represents means
± SEM for three separate determinations performed in triplicate (N=3).

Subcutaneous Xenograft of MDA-MB-231 Cells
NOD-Rag1null Il2rgnull (NRG) mice, provided by Dr. Levi Beverly’s
laboratory, were housed in the University of Louisville animal facility and the
experiment was reviewed and approved by the University’s Institutional Animal
Care and Use Committee. The parental (N=10) and knockout (N=5 for each
knockout cell line) MDA-MB-231 cell lines (1 X 106) were injected
subcutaneously into the right or left flank, respectively, of 18 week old female
NRG mice. Tumors where collected after six weeks, and weighed before being
flash frozen. The data are represented as means ± SEM, and were analyzed
statistically by one-way ANOVA and Bonferroni post hoc test.
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RESULTS

NAT1 Genomic and Amino Acid Sequence
Sequencing for MDA-MB-231 cell lines characterized gRNA #2 (clone 219) knockout cell line with a deletion in the open reading frame, which is the
deletion of a cytosine nucleotide at base 96 of 870 bp (table 5.1). This single
nucleotide deletion resulted in a frameshift causing a premature stop codon after
amino acid 49 of 290 (table 5.2). The gRNA #5 (clone 5-50) knockout cell line
had two nucleotides deleted at 43 and 44 bp downstream of the start codon
(table 5.1). This deletion resulted in a premature stop codon after amino acid
codon 14 of 290, which immediately terminates translation of NAT1 (table 5.2).

Sequencing results for MCF7 show that gRNA #2 (clone 2-4) knockout cell
line has a 34 bp deletion in the open reading frame, which spans from 95 to 129
bp (table 5.3). This deleted segment of DNA resulted in a frameshift causing a
premature stop codon after 38 amino acids (table 5.4). The gRNA #5 (clone 520) knockout cell line had two separate deletions. The first deletion was a single
nucleotide deletion at bp 42, and the other was a deletion of bp 43 to bp 48 with
an adenine insertion in the same region (table 5.3). These indel deletions
resulted in a premature stop codon after amino acid codon 23 for both
sequences (table 5.4).
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Table 5.1 – Genomic sequence for the NAT1 gene in MDA-MB-231 Parental and NAT1 knockout clones

Cell line
Parental
gRNA #2 clone
Parental
gRNA #5 clone

bp #
76
76
21
21

Genomic Sequence
GACATTCTTCAACACCAGATCCGAGCTGTT
GACATTCTTCAACACCAGATC-GAGCTGTT
TGAAAGAATTGGCTATAAGAAGTCTAGGAA
TGAAAGAATTGGCTATAAGAAG--TAGGAA

bp#
105
105
50
50

102

Table 5.2 – Resulting Amino Acid Sequence for MDA-MB-231 Parental and NAT1 knockout clones

Cell line
Parental

103

gRNA #2
clone
gRNA #5
clone

Amino
M D I
Q H Q
D Q V
E T T
T I D
K D Q
Y I P
R T I
L Q T
I E F
P K H
M D I
Q H Q
M D I

Acid Sequence
E A Y L E R I
I R A V P F E
V R R N R G G
M L G G Y V Y
G R N Y I V D
P Q V P C I F
N E E F L H S
E D F E S M N
P D G V H C L
K T L S E E E
G D R F F T I
E A Y L E R I
I E L F P L R
E A Y L E R I

G Y K
N L N
W C L
S T P
A G F
R L T
D L L
T Y L
V G F
I E K
Stop
G Y K
T L T
G Y K

K
I
Q
A
G
E
E
Q
T
V

S
H
V
K
R
E
D
T
L
L

R
C
N
K
S
N
S
S
T
K

N
G
H
Y
Y
G
K
P
H
N

K
D
L
S
Q
F
Y
A
R
I

L
A
L
T
M
W
R
S
R
F

D
M
Y
G
W
Y
K
V
F
N

L
D
W
M
Q
L
I
F
N
I

E
L
A
I
P
D
Y
T
Y
S

T
G
L
H
L
Q
S
S
K
L

L
L
T
L
E
I
F
K
D
Q

T
E
T
L
L
R
T
S
N
R

D
A
I
L
I
R
L
F
T
K

I
I
G
Q
S
E
K
C
D
L

L
F
F
V
G
Q
P
S
L
V

K S R N K L D L E T L T D I L
S I V G M P W T Stop
K Stop

# of AA
290

49
14

Table 5.3 – Genomic sequence for the NAT1 gene in MCF7 Parental and NAT1 knockout clones

Cell line
Parental
gRNA #2
clone
Parental
gRNA #5
clone
gRNA #5
clone

bp #
91

Genomic Sequence
CAGATCCGAGCTGTTCCCTTTGAGAACCTTAACATCCATTGTGGG

bp#
135

91

CAGAT----------------------------------TGTGGG

135

31

GGCTATAAGAAGTCTAGGAACAAATTGGAC

60

31

GGCTATAAGAA-TCTAGGAACAAATTGGAC

60

31

GGCTATAAGAAGA-----AACAAATTGGAC

60
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Table 5.4 – Resulting Amino Acid Sequence for MCF7 Parental and NAT1 knockout clones

Cell line
Parental

105

gRNA #2
clone
gRNA #5
clone
gRNA #5
clone

Amino
M D I
Q H Q
D Q V
E T T
T I D
K D Q
Y I P
R T I
L Q T
I E F
P K H
M D I
Q H Q
M D I

Acid Sequence
E A Y L E R I
I R A V P F E
V R R N R G G
M L G G Y V Y
G R N Y I V D
P Q V P C I F
N E E F L H S
E D F E S M N
P D G V H C L
K T L S E E E
G D R F F T I
E A Y L E R I
I V G M P W T
E A Y L E R I

G Y K
N L N
W C L
S T P
A G F
R L T
D L L
T Y L
V G F
I E K
Stop
G Y K
Stop
G Y K

K
I
Q
A
G
E
E
Q
T
V

S
H
V
K
R
E
D
T
L
L

R
C
N
K
S
N
S
S
T
K

N
G
H
Y
Y
G
K
P
H
N

K
D
L
S
Q
F
Y
A
R
I

L
A
L
T
M
W
R
S
R
F

D
M
Y
G
W
Y
K
V
F
N

L
D
W
M
Q
L
I
F
N
I

E
L
A
I
P
D
Y
T
Y
S

T
G
L
H
L
Q
S
S
K
L

L
L
T
L
E
I
F
K
D
Q

T
E
T
L
L
R
T
S
N
R

D
A
I
L
I
R
L
F
T
K

I
I
G
Q
S
E
K
C
D
L

L
F
F
V
G
Q
P
S
L
V

# of AA
290

K S R N K L D L E T L T D I L

38

N L G T N W T W K H Stop

23

M D I E A Y L E R I G Y K K K Q I G L G N I N Stop

23

In Vitro and In Situ PABA Acetylation Activity
The in vitro N-acetylation of PABA in MDA-MB-231 parental cell was 14.4
± 1.63 nmoles/min/mg of protein (figure 5.1A). The CRISPR gRNA #2 and #5
clones reduced levels of activity to below a detectable level, with the limit of
detection 0.05 nmoles/min/mg of protein (figure 5.1A). The N-acetylation of
PABA in situ per hour per million cells followed the same pattern as the in vitro
activity. N-acetylation of PABA in the parental MDA-MB-231 cell line activity was
1.15 ± 0.022 nmoles/hr/million cells (figure 5.1C). In the gRNA #2 and #5 clones,
levels of PABA N-acetylation in situ were reduced to below a detectable level,
with the limit of detection 0.20 nmoles/hr/million cells (figure 5.1C).

The in vitro acetylation of PABA activity for MCF7 parental cell lysates was
39.0 ± 3.42 nmoles/min/mg of protein (figure 5.1B). The CRISPR gRNA #2 and
#5 clones had levels of activity reduced to below a detectable level, with the limit
of detection 0.05 nmoles/min/mg of protein (figure 5.1B). The N-acetylation of
PABA in situ per hour per million cells followed the same pattern as the in vitro
activity. N-acetylation of PABA in the parental MCF7 cell line was 2.20 ± 0.357
nmoles/hr/million cells (figure 5.1D). In the gRNA #2 and #5 clones, levels of
PABA N-acetylation in situ were reduced to below a detectable level, with the
limit

of

detection

0.20

nmoles/hr/million

106

cells

(figure

5.1D).

Endogenous AcCoA Levels
The endogenous level of AcCoA within the MDA-MB-231 parental cell line
was 17.8 ± 1.1 pmoles/million cells (figure 5.1E). The endogenous level of
AcCoA within the cells of the gRNA #2 and #5 NAT1 knockout clones was 33.1 ±
1.8 and 35.5 ± 2.6 pmoles/million cells, respectively (figure 5.1E). Overall
endogenous levels of AcCoA within the gRNA #2 and #5 NAT1 knockout clones
were significantly elevated compared to their MDA-MB-231 parental cell line
(N=8; p<0.05) (figure 5.1E).

MCF7 parental cell line had an endogenous level of AcCoA of 18.7 ±
0.897 pmoles/million cells (figure 5.1F). The endogenous levels of AcCoA within
the cells of the gRNA #2 and #5 NAT1 knockout clones were 27.6 ± 2.60 and
27.0 ± 2.72 pmoles/million cells, respectively (figure 5.1F). Overall endogenous
levels of AcCoA within the gRNA #2 and #5 NAT1 knockout clones were
significantly elevated compared to their MCF7 parental cell line (N=12; p<0.05)
(figure 5.1F).
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Figure 5.1 - NAT1 PABA acetylation activity and endogenous AcCoA
concentration level in genomic modified MDA-MB-231 and MCF7 cell lines. Each
bar illustrates mean ± SEM. The in vitro PABA N-acetylation (A-B) activity in cell
line lysates (N=3). The in situ PABA N-acetylation (C-D) in MDA-MB-231 (N=3)
and MCF7 (N=4) cell lines cultured in PABA spiked media. The endogenous
AcCoA levels (E-F) for MDA-MB-231 (N=8) and MCF7 (N=12) cell lines.
Differences between cell lines were significantly different (* p≤ 0.05; *** p≤ 0.001)
following one-way ANOVA with a Bonferroni post-test.
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Cell Line Doubling Times
The doubling times for the parental cell line and gRNA #2 and #5 NAT1
knockout cell lines were 30.5 ± 1.0, 29.3 ± 1.1, and 29.8 ± 0.7 hours, respectively
(N=3)(figure 5.2A). Neither of the gRNA NAT1 knockout clone cell lines
significantly altered the doubling time compared to the parental MDA-MB-231 cell
line. Differences were tested for statistical significance by one-way ANOVA (p>
0.05).

MCF7 parental cell line and gRNA #2 and #5 NAT1 knockout cell lines
exhibited doubling times of 41.4 ± 0.4, 45.3 ± 6.2, and 38.8 ± 8.5 hours,
respectively (N=3)(figure 5.2B). Neither of the gRNA NAT1 knockout clone cell
lines significantly affected the doubling time compared to the parental MCF7 cell
line. Differences were tested for statistical significance by one-way ANOVA (p>
0.05).

Anchorage-Dependent and -Independent Colony Formation Assay
The ability of colony formation by anchorage-dependent manner was
quantified for MDA-MB-231 parental (40.7 ± 2.54 colonies) and gRNA #2 (51.3 ±
1.61 colonies) and #5 (54.8 ± 6.76 colonies) NAT1 knockout modified cell lines.
Anchorage-dependent colonies among the MDA-MB-231 and NAT1 knockout
cell lines did not differ statistically from each other tested by a one-way ANOVA
followed by Bonferroni post hoc test (p>0.05; N=6) (figure 5.2C).
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MCF7 parental and gRNA #2 and #5 NAT1 knockout modified cell lines
ability of colony formation by anchorage-dependent manner was quantified as
50.7 ± 5.2, 80.6 ± 6.4, and 41.5 ± 6.2 colonies, respectively. MCF7 gRNA #2
clone cell line formed statistically more colonies than the parental and gRNA #5
clone cell lines when tested by a one-way ANOVA followed by Bonferroni post
hoc test (p<0.0005; N=7) (figure 5.2D).

Anchorage-independent colony formation assays (also known as “soft
agar assays”) allow for the determination of cancer cell ability to form colonies in
the absence of cellular attachment to a surface. The MDA-MB-231 parental cell
line formed anchorage-independent colonies at markedly higher levels than the
NAT1 knockout clones (figure 5.2E). The number of colonies formed by MDAMB-231 parental and gRNA #2 and #5 NAT1 knockout modified cell lines were
1070 ± 76, 48.3 ± 17.2, and 23.4 ± 7.0 colonies, respectively. The anchorageindependent colony formation of MDA-MB-231 parental cell line was significantly
higher than their CRISPR NAT1 knockout peers when tested by one-way
ANOVA followed by Bonferroni post hoc test (p<0.0001; N=3). The same
Bonferroni post test showed that the two CRISPR NAT1 knockout cell lines were
not statistically (p>0.05) different from each other.

MCF7 parental cell line formed anchorage-independent colonies at a
higher level than the NAT1 knockout MCF7 cell line clones (figure 5.2F). The
number of colonies formed by MCF7 parental and gRNA #2 and #5 NAT1
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knockout cell lines were 195 ± 9, 33.7 ± 6.8, and 13.8 ± 6.6, respectively.
Anchorage-independent colonies formed by the MCF7 parental cell line were
significantly higher than gRNA #2 and #5 NAT1 knockout clones by one-way
ANOVA followed by Bonferroni post hoc test (p<0.0001; N=4). The MCF7 gRNA
#2 and #5 NAT1 knockout clones were not statistically different (p>0.05) from
each other.
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FIGURE 5.2
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Figure 5.2 - Cell growth properties in genomic modified MDA-MB-231 and MCF7
cell lines. Each bar illustrates mean ± SEM. Cell doubling times (A-B) in MDAMB-231 and MCF7 NAT1 knockout cell lines did not differ significantly from
parental cell lines following one-way ANOVA (p>0.05) (N=3). The anchoragedependent growth (C) did not differ significantly among the MDA-MB-231 cell
lines following one-way ANOVA (p>0.05) (N=6). MCF7 CRISPR gRNA #2 clone
cell line formed more anchorage-dependent colonies than the parental and
CRISPR gRNA #5 clone cell lines (D) according to an one-way ANOVA followed
by a Bonferroni post-test (** p≤ 0.001 and *** p≤ 0.001) (N=7). The NAT1
knockout cell lines formed significantly less anchorage-independent colonies
compared to parental cell lines (E-F) for both MDA-MB-231 (N=3) and MCF7
(N=4) determined by one-way ANOVA followed by a Bonferroni post-test (*** p≤
0.001). No significant differences in anchorage-independent colonies between
the gRNA #2 and #5 of MDA-MB-231 (N=3) and MCF7 (N=4) (p>0.05).
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Anoikis Assay and Hanging Drop Assay
Cancer cells were measured for anoikis resistance by being cultured
under anchorage independent conditions. Anchorage independent growth
conditions were achieved by coating wells of a 96-well plate with poly-HEMA,
which keeps cells from attaching to the bottom of the well. In anchorage
independent growth conditions the growth curves of MDA-MB-231 parental and
gRNA #2 and #5 knockout cell lines do not significantly differ from their
respective cells grown in anchorage dependent conditions (N=3)(figure 5.3 A-C).
When parental and NAT1 knockout clones are compared between each growth
condition there was no significant difference observed (figure 5.3D and E).

To address the growth of MDA-MB-231 parental and knockout cell lines in
anchorage independent growth conditions and in close cellular proximity a
hanging drop assay was conducted. The results suggest that over the course of
time knockout of NAT1 within MDA-MB-231 cancer cells results in aggregating
and forming a mass of cells sooner that the parental cell line (figure 5.4A). If the
ratio of dead cells to live cells is measured by trypan blue exclusion, the gRNA
#2 and #5 NAT1 knockout clone cell lines developed a higher ratio of dead cells
to live cells compared to the parental MDA-MB-231 cell line according to a twoway ANOVA (figure 5.4B) (interaction p<0.0001, N=7). At the 72 hour time point
both the gRNA #2 and #5 NAT1 knockout clone cell lines had significantly higher
ratio of dead cells to live cells compared to the parental cell line (figure 5.4B)
(p<0.01, N=7).
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Invasion Assay
The relative invasion ability of MDA-MB-231 parental and gRNA #2 and #5
NAT1 knockout clones were found not to differ significantly when compared by a
by one-way ANOVA and Bonferroni post hoc test (p>0.05; N=4)(figure 5.5B).

Wound Closure for MDA-MB-231 Cell Lines
MDA-MB-231 gRNA #2 and #5 NAT1 knockout clone cell lines closed
more of a wound than the MDA-MB-231 parental cell line parental cell lines
(figure 5.6A). The linear slopes for the NAT1 knockout cell lines were found to be
significantly higher than the linear slope of the parental cell line (p<0.01; N=3)
(figure 5.6B).

Subcutaneous Xenograft of MDA-MB-231 Cell Lines
The removed xenograft tumors of MDA-MB-231 cells weighed 0.448 ±
0.0696 grams for parental cell line, 0.308 ± 0.0515 grams for gRNA #2 NAT1
knockout clone, and 0.463 ± 0.128 grams for gRNA #5 NAT1 knockout clone.
There was no difference in the total tumor weights of the isolated tumors
between the parental and CRISPR clones (p>0.05) (figure 5.7).
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Figure 5.3 - Growth curves for MDA-MB-231 cell lines with standard adhesion or
in anchorage-independent conditions. Parental and CRISPR gRNA knockout
clone cell lines growth curves comparing their ability to grow in standard noncoated wells versus poly-HEMA coated wells (anchorage independent
conditions) (A-C). Parental and the CRISPR/Cas9-mediated NAT1 knockouts
display a level of anoikis resistance when compared to standard anchorage
growth. Comparisons of the two different conditions for each cell line found no
statistical difference (A, p=0.63; N=3 / B. p=0.88; N=3 / C, p=0.72; N=3). The
NAT1 knockout cell lines have comparable growth and anoikis resistance to the
parental MDA-MB-231 cell lines over the course of 96 hours (D-E).
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FIGURE 5.4
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Figure 5.4 – Comparison of representative photomicrographs taken of the
hanging drops showing the cells four days (A). The CRISPR knockout MDA-MB231 clone cell lines (#2 and #5) each form tightly packed, often singular, cellular
masses. However the parental MDA-MB-231 cells remain relatively diffused by
the fourth day. The cells are collected and counted using trypan blue exclusion to
determine the ratio of “dead cells” to “live cells” within a drop (B). The parental
MDA-MB-231 cells seem to remain at the same ratio of dead to live cells over the
course of three days. However NAT1 knockout clones increase in the ratio of
dead cells to live cells over the course of days. This is found to be significantly
different by two-way ANOVA (interaction p<0.0001; N=7) followed by a
Bonferroni post hoc test (** p≤ 0.01; *** p≤ 0.001 for the 72 hour time point).
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FIGURE 5.5
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Figure 5.5 –Comparison of photomicrographs taken of Transwell® membranes
illustrating the different number of cells that were able to reach the bottom side of
the membrane either with or without Matrigel for parental or NAT1 knockout cell
lines (A). The gel concentration is given along the top of the columns as mg/ml,
and then directly below is the number of cells that were seeded into the
Transwell® insert. Relative Invasion ability for either MDA-MB-231 parental or
NAT1 knockout cell lines (B). Relative invasiveness was calculated by dividing
the cells that invaded thru the 0.5 mg/ml gel matrix (insert seeded with 50,000
cells) by the number of cells that migrated through no gel (insert seeded with
25,000 cells). The relative invasiveness ability for each cell line was nonsignificant different (p=0.19; N= 4).
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FIGURE 5.6
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Figure 5.6 – Percentage of closure for a 2 mm diameter wound over the course
96 hours. The CRISPR gRNA #2 and #5 NAT1 knockout clone cell lines have a
higher percentage of closure that the MDA-MB-231 parental cell line over the 96
hours (A). The rate of closure is elevated in the NAT1 knockout cell lines
compared to the rate for the parental MDA-MB-231 cell line (B). This elevated
rate for NAT1 knock out cells was found to be significant by a one-way ANOVA
followed by a Bonferroni post hoc test (* p≤ 0.05; ** p≤ 0.01; N=3).
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Figure 5.7 – The removed xenograft tumor weights for MDA-MB-231 parental
(N=10), gRNA #2 clone (N=5) and gRNA #5 clone (N=5) were not significantly
different from each other as determined by a one-way ANOVA (p=0.454).
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DISCUSSION

CRISPR/Cas9 was used to produce cloned cell lines with a stable
knockout of NAT1 in human MDA-MB-231 and MCF7 breast cancer cell lines.
This study served to replicate previous findings with partial shRNA knockdowns,
and confirmed differences in human NAT1 expression effects within breast
cancer cell lines. Differences in human NAT1 expression have been reported to
alter cancer cell growth properties, and understanding how NAT1 gene
expression affects cancer cell growth characteristics is very important.

MDA-MB-231 and MCF7 gRNA #2 and #5 NAT1 knockout clones resulted
in no measurable PABA acetylation either in vitro or in situ assays, at least a
45% increase of endogenous AcCoA levels, and at least a 6-fold decrease in
anchorage-independent growth compared to the parental MDA-MB-231 and
MCF7 cell lines. However knockout of NAT1 produced no significant changes
(p>0.05) in cell doubling time, anchorage-dependent growth, or relative invasion
ability compared to parental MDA-MB-231 cells. MCF7 parental and knockout
clone cell lines showed no significant difference (p>0.05) in doubling time. The
MCF7 gRNA #2 clone formed more anchorage-dependent colonies that the
MCF7 parental and gRNA #5 clone cell lines. This elevation of colonies in MCF7
gRNA #2 clone is not related to the knockout of NAT1 since it is not found in the
MCF7 gRNA #5 clone, and the results from other model systems show no
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increase in anchorage-dependent colonies. So this increase can be the result of
an off target effect.

The combined results with NAT1 knockout cell lines show no difference in
doubling time compared to the parental cell lines. The number of anchoragedependent colonies was found to be independent of the NAT1 activity level in
these breast cancer cell lines. The relative cellular invasion ability was found to
be non-significantly different between MDA-MB-231 parental cells and NAT1
knockout cells. These findings suggest that NAT1 does not play a role in growth
rates, anchorage-dependent colony formation, or relative invasion ability for
breast cancer cells under cell culture conditions. This conclusion is different from
that of previous reports [11, 12].

NAT1 hydrolysis of AcCoA in the presence of folate compounds suggests
that NAT1 may affect endogenous levels of AcCoA [54, 103]. Consistent with this
concept, NAT1 knockout elevated AcCoA levels in both the MDA-MB-231 and
MCF7 cell line model systems. Rat embryonic fibroblasts from rapid acetylator
congenic rats have lower levels of AcCoA than rat embryonic fibroblasts derived
from slow acetylator congenic rats [65]. Partial knockdown of NAT1 in MDA-MB231 also showed elevated levels of AcCoA compared to the wildtype (scramble
shRNA) MDA-MB-231 cell line. A direct connection for physiological differences
in AcCoA levels drawn to NAT1 AcCoA hydrolysis requires further investigation.
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However the current accumulating data show that NAT1 influences endogenous
AcCoA levels.

Anchorage-independent growth decreased 12-fold in MDA-MB-231 and 6fold in MCF7 cells when NAT1 activity was knocked out. Based on this result, it is
hypothesized that the removal of NAT1 activity reestablished anoikis ability within
the cell lines. Anoikis is an anchorage-related apoptosis that results from the loss
of integrin-mediated cell-matrix contact. In the absence of attachment to
extracellular matrix (ECM) or upon cell adhesion to inappropriate location, cells
undergo this type of apoptosis. Integrin receptors mediate the cell to ECM
interactions providing physical links with the cytoskeleton and transduce signals
from the ECM to the cell. The transduction of signals is mandatory for several
cellular processes including migration, proliferation and survival [148-151].
Anoikis serves as a defense mechanism within an organism. The defense
mechanism prevents detached cells reattaching to incorrect ECM locations and
proliferating. Cells that lack or have a reduced anoikis response can result in
cells surviving under suspension conditions and/or proliferating at ectopic sites
with a different ECM. Decreased regulation of anoikis is emerging as a hallmark
of cancer cells and contributes to the formation of metastasis in distant organs
[148-151].

However testing for reestablishment of anoikis revealed that anchorage
independent growth rates, determined from growth in poly-HEMA coated plates,
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were not different between MDA-MB-231 parental and NAT1 knockout clone cell
lines. This finding means that anoikis is unlikely the cause of the dramatic
differences in anchorage-independent colony formation. A hanging drop assay
revealed an elevated ratio of dead to live NAT1 knockout cells compared to the
parental cell line. In the hanging drop assay, the cells grow in anchorageindependent conditions, but are forced to gradually come into contact with each
other. This result is suggestive that the NAT1 knockout cell lines are more
sensitive to the cell-cell contacts than the parental cell line. So instead of anoikis
reestablishment, the close proximity of other cells may be the cause for a lower
number of anchorage-independent colonies. The wound closure assay with
MDA-MB-231 cells showed that NAT1 knockout cell lines enter an open growth
area at higher rates compared to the parental cell line, which was observed in the
closure rates for each cell line.

Subcutaneous xenograft of MDA-MB-231 NAT1 knockout cells developed
into a tumor with the same masses as the parental cells. This result is consistent
with cell culture results showing no difference in anchorage-dependent growth. A
future experiment with tail vein injections of cancer cells and measuring lung
metastasis may result in the NAT1 knockout cells producing lower tumor rates
than parental cells. This theory is based on published data using similar methods
[12]. Also this methodology of tail vein injection requires cancer cells to flow
through the blood stream and grow from individual cells into a lung metastasis,

123

which is a better representation of the cell culture anchorage-independent
findings.

In summary, our findings compliment but do not fully replicate previous
reports regarding the effect of reducing NAT1 activity on cancer cell properties. In
our studies, complete removal of NAT1-catalyzed N-acetylation in the MDA-MB231 and MCF7 breast cancer cell line by CRISPR/Cas9 resulted in a significant
decrease in anchorage-independent colony formation without affecting overall
cell growth and relative invasion ability. NAT1 knockout cell lines had increased
endogenous AcCoA levels, about 45%, compared to the parental cell line. The
results warrant further studies to determine mechanisms to understand how
reduced NAT1 activity is related to reduced formation of anchorage-independent
colonies. Use of this model system further suggests that human NAT1 could
serve as a target for the prevention and/or treatment of breast cancer.
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CHAPTER VI
SUMMARY AND CONCLUSIONS
The results presented within this dissertation show the possible role of
NAT1 in tumorigenesis and cell biology. To come upon these results experiments
were conducted using in vitro enzymatic reactions, in vivo studies with
homozygous high (rapid) or low (slow) NAT2 activity congenic rats, and
genetically modified cancer cell lines. The second chapter shows that human
NAT1 and rodent NAT2 hydrolyze AcCoA in a folate dependent manner. The
third chapter shows that rapid NAT2 congenic rats develop more tumors than the
slow NAT2 congenic strain following administration of MNU and DMBA
carcinogens, which are both not metabolized by rat NAT2. The fourth and fifth
chapters are studies performed with partial NAT1 knockdown and complete
NAT1 knockout human breast cancer cell lines, respectively. The findings conflict
with some previous findings on knockdown cell lines, but also share a common
result. In both the partial knockdown and complete knockout cell lines
anchorage-independent colony formation ability in soft agar is greatly diminished
compared to parental cell lines. Endogenous AcCoA levels in congenic slow
NAT2 rat embryonic fibroblasts, partial NAT1 knockdown cell line, and complete
NAT1 knockout cell lines show increased AcCoA when NAT activity is reduced
within the cell. The “complete mechanism/role” of NAT1 is still debatable,
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however this dissertation provides evidence that NAT1 influences mammary
cancer susceptibility and has an endogenous role within a cell.

The second chapter, first results section, shows human NAT1 and the
rodent ortholog NAT2 can perform AcCoA hydrolysis in the presence of folate but
absence of xenobiotic substrate (e.g. PABA). The human NAT2 and the rodent
Nat1 have no detectable AcCoA hydrolysis activity. A HPLC method was
developed to measure the level of CoA and AcCoA. We determined the
Michaelis-Menton kinetic constants (Vmax and Km) for both AcCoA and folate
using human NAT1 as well as three rodent Nat2 enzymes. The fact that folate
and DHF support the AcCoA hydrolysis activity makes it a possible endogenous
activity within a cell. MTX, a folate analog, was not able to support hydrolysis of
AcCoA to any considerable degree. All these in vitro studies strengthen the
position that NAT1 can perform an endogenous reaction independent of a
xenobiotic substrate.

The third chapter suggests that human NAT1, with the use of the ortholog
rat Nat2 in congenic rats, plays an important role in tumorigenic incidence and
onset. The strengths of this study are the congenic rat model and the similarity of
human NAT1 and rat NAT2. The Hein laboratory made the congenic Fischer 344
rat strains several years ago, and characterized the differences between rapid
and slow Nat2 congenic rats in previous publications. The rapid and slow NAT2
congenic F344 rat stains were derived by the same breeding approach, so the
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genetic background of rapid and slow congenic rats is more than 99.9% similar.
This very close similarity allows us to compare rapid and slow NAT2 with minimal
influence of strain differences besides the NAT2 gene. As mentioned in the
introduction, human NAT1 and rat NAT2 share over 83% amino acid sequence
homology, with no differences in the active site or the C-terminal tail. The rat
breast cancer model is a strength because we can measure palpable tumors in
live animals over time. In theory this study could be conducted on almost any
form of cancer.

Chemically induced tumors are affected by variable, yet controllable,
factors like the inducing carcinogen, age of administration, reproductive history,
and diet. Diet and reproductive history of these rats are the same for both rapid
and slow congenic rats. Administration of MNU is an approached used for
several decades to induce mammary tumors in rodents. MNU is a direct acting
DNA alkylating agent that does not need biotransformation to form DNA adducts.
It has been shown that sexually immature F344 rats (at 3 weeks of age) are more
susceptible to mammary carcinogenesis by MNU than mature rats (8 weeks of
age) [77]. In chapter three, MNU was given at both 3 and 8 weeks of age to
ensure no possible developmental differences were affecting the results.
Additionally, rats were treated with another well-studied and utilized carcinogen,
DMBA, at eight weeks of age. DMBA is a procarcinogen that requires enzymatic
metabolism to become an active carcinogen. The enzymes that activate DMBA
have been characterized and do not involve human NAT1/rat NAT2. The use of
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DMBA shows that tumorigenic differences between rapid and slow NAT2
congenic rats are not carcinogen related. The study in chapter three is
strengthened by the different approaches to address the factors that can
influence chemically induced tumors.

The use of rat embryonic fibroblasts (REFs) to measure the endogenous
AcCoA levels of rapid and slow congenic strains is necessary in this study. The
ability to normalize the small amount of detectable AcCoA from HPLC to the
number of cells is considerably more reliable and reproducible than the extensive
trials using whole tissue from congenic rats. Whole tissue suffered from
considerable variability in the data from tissue weights and tissue composition.
REFs serve to strengthen this study by greatly increasing the reliability of the
data.

The results in the fourth and fifth chapters use two separate models: a
partial knockdown and a knockout of NAT1. In both of these model systems, no
effect on doubling time, number of anchorage-dependent colonies, relative
cellular invasion ability were found to be non-significantly different between
wildtype NAT1 activity cells and NAT1 knockout breast cancer cell lines. These
repetitive findings suggest that NAT1 does not play a role in growth rates,
anchorage-dependent colony formation, or relative invasion ability for breast
cancer cells under cell culture conditions. This conclusion differs from that of
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previous studies by others [11, 12], but is strongly supported by the different
models and cell lines used within this dissertation.

In the fourth chapter despite a 12-fold overexpression of NAT1 in vitro
activity, significant (p<0.05) changes in endogenous AcCoA levels, cell doubling
time, anchorage-dependent growth, anchorage-independent cell growth, or
relative invasion ability were not observed. In contrast, a previous study using
HB4a cells reported that NAT1 overexpression resulted in enhanced growth
properties [8]. The MDA-MB-231 cells used in the present study are a claudinlow, triple-negative breast cancer cell line whereas the HB4a cell line is derived
from normal luminal mammary epithelial cells. Thus, the lack of differences
between scrambled shRNA and NAT1 overexpression MDA-MB-231 cell lines
may be a result of the cell line utilized. It is also possible that NAT1 has a type of
threshold effect where increasing NAT1 activity within a cell does not result in a
significant difference as with knockdown of NAT1 activity. The reduced NAT1
activity studies could be further strengthened with the inclusion of reestablishing
the NAT1 activity once it has been completely knocked out. Theoretically the
difference in anchorage-independent colony formation and the endogenous
AcCoA level should be restored to that of the parental cell line. The reestablished
NAT1 activity cell lines are currently being developed and explored within the
Hein laboratory.
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Chapters III, IV, and V all explore the concept presented in chapter II,
which is that in the presence of folate, NAT1 is able to hydrolyze AcCoA.
Consistent with this concept, endogenous AcCoA levels in congenic rat
embryonic fibroblasts, partial NAT1 knockdown cell line, and complete NAT1
knockout cell lines showed increased AcCoA when the level of NAT1 activity is
reduced within the cell. The complete NAT1 knockout in MDA-MB-231 cell lines
elevated endogenous AcCoA levels by 86% to 99%. The complete NAT1
knockout in MCF7 elevated endogenous AcCoA levels by 45% to 48%. These
findings are consistent with folate-dependent AcCoA hydrolysis catalyzed by
NAT1. However the findings do not provide conclusive evidence that the folatedependent hydrolysis is the primary or sole mechanism for the elevation of
AcCoA.

Differences in AcCoA levels could provide an explanation for differences
in metabolites of fatty acid synthesis and amino acids [131]. The effects of NAT1
on anchorage-independent cell growth and endogenous AcCoA levels may
provide insight into why congenic rapid NAT2 rats developed more mammary
tumors than congenic slow NAT2 rats following administration of mammary
carcinogens that are not metabolized by rat NAT2 [65].

This dissertation provides evidence that NAT1 influences mammary
cancer susceptibility and has an endogenous role within a cell. The “complete
mechanism/role” of NAT1 is still debatable. The mechanism/role discussed within
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this dissertation focused on NAT1 influence over AcCoA concentrations. Future
experiments will need to be done to fully understand the ramifications and
benefits of removing NAT1 activity from a cell.
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CHAPTER VII
FUTURE DIRECTIONS

This chapter serves to provide future experiments to expand upon the
results within this dissertation. The results of this dissertation indicate NAT1 has
a role in tumorigenesis, anchorage-independent colony formation, and cellular
AcCoA concentrations. The future directions based off these findings are diverse
in scope from exploring the role NAT1 might play in DNA damage to exploring
how altered levels of one of the most important biology compounds, AcCoA, can
affect cellular functions.

In chapter three, slow NAT2 congenic rats had fewer mammary tumors
than rapid NAT2 congenic rats following administration carcinogens (MNU and
DMBA) that are not metabolized by rat NAT2. The difference in tumor incidence
between the congenic rat strains is hypothesized to be the result of difference in
DNA damage repair. The first possible experiment is measuring total DNA
damage in the rapid and slow congenic rats from MNU by alkaline comet assay.
The other experiment could be measuring the level of H-Ras and K-Ras
mutations resulting from MNU exposure. While measuring the frequency of
mutations is not a measure of DNA damage, the mutations are a result of
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inappropriate DNA repair. These experiments will inform how rat NAT2 activity
can influence tumorigenic differences.

The comet assay, also known as single-cell gel electrophoresis assay, is a
simple and sensitive technique for the detection of DNA damage and repair in
cell lines. A commonly used comet assay is the alkaline comet assay, which is
performed under high pH (>13). The alkaline comet assay is optimal for
assessing agents with genotoxic activity [152]. The alkaline comet assay is able
to detect single-strand breaks, double-strand breaks, and other damage to DNA.
As discussed in the chapter three, the methylnitrosourea (MNU) mechanism to
cause cancer is DNA damage resulting from the alkylation of nitrogen and
oxygen in DNA leading to mutations (figure 3.2). MNU exposure strategy for cell
lines has been established, and analyzed by alkaline comet assay [153]. The rat
embryonic fibroblasts (REFs) isolated from the congenic rat model in chapter
three can be used with an alkaline comet assay. The REFs could be exposed to
MNU in situ and DNA damage quantified over time. The expected result is that
slow NAT2 REFs would have reduced levels of DNA damage compared to the
rapid NAT2 REFs. The parental and NAT1 modified MDA-MB-231 and MCF7
breast cancer cell lines could also be used with the alkaline comet assay
following MNU exposure. Preliminary studies have been performed with the
MDA-MB-231 parental and NAT1 knockout clone cell lines. Currently there is a
trend of the NAT1 knockout MDA-MB-231 clones having less DNA damage than
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the parental cells at 24 hours post MNU exposure. Additional experiments are
needed to confirm that NAT1 knockout serves to reduce DNA damage.

In classical chemical carcinogenesis studies, MNU is shown to commonly
target the second base of codon 12 of H-Ras and K-Ras to generate a G12D
mutation [97, 154-158]. This common mutation on codon 12 of H-Ras and K-Ras
caused by MNU can be used to assess the frequency of mutation between rapid
and slow NAT2 congenic rats. A study using isolated rapid and slow NAT2 REFs
to assess the mutation frequency of Ras codon 12 following in situ MNU
exposure would determine any mutation frequency difference. The expected
result would be the slow NAT2 REFs have a lower frequency of the mutation
compared to the rapid NAT2 REFs after MNU exposure. The use of MDA-MB231 and MCF7 NAT1 knockout clones could also be used instead of REFs to
quantify the frequency of codon 12 mutations. MCF7 cell line does not contain
any mutations at the codon 12 for H-RAS and K-Ras [159]. MDA-MB-231 cell line
also has no mutations for the codon 12 in H-Ras and K-Ras, however there is a
known mutation in K-Ras codon 13 (G13D) [159]. The quantification of MNU
induced mutation at codon 12 can be done with competitive, allele-specific
TaqMan™ PCR (castPCR) (Life Technologies™, California, USA) [160]. This
experiment would answer if NAT1 knockout could help cells repair DNA damage
with a lower frequency of DNA mutations.
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Additional experiments in relationship to the finding in chapter three range
from repeat experiments in new animal models to use of new carcinogens. While
considerable effort was put forward to minimize the differences between rapid
and slow NAT2 congenic rats, it is still only one animal model. This use of only
one animal model is a weakness in the study from chapter three. The addition of
different animal models with altered rodent NAT2 activity, such as mouse and
hamster, would serve to strengthen tumorigenic study findings [52, 57-59, 161].
Another interesting study would be the effect of mammary tumor mastectomies
on tumor re-occurrence between the rapid and slow NAT2 congenic rats.
Mammary tumors would be induced with MNU or DBMA, and upon the first
palpable mass perform a mastectomy to remove the mammary gland to
subsequently observe if the mastectomy provided increased tumor free periods
for either the rapid or slow NAT2 congenic rats. The results of this study could
help guide clinical decisions, when a woman with higher or lower levels of NAT1
activity is diagnosed with breast cancer. Also since rodent NAT2 is known to
have wide tissue distribution, conducting chemically induced tumorigenic
experiments in other tissues should show similar results to the mammary gland
tumor incidence. There are numerous published chemically induced tumor
animal models with detailed mechanism information. As with the MNU and
DMBA, carcinogens should be selected that do not require metabolic activation
or deactivation by human NAT1/rat NAT2.
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In chapter four and five, anchorage-independent colony formation is
decreased whenever NAT1 activity is reduced. This raises the question as to
how NAT1 is able to influence this anchorage-independent colony formation
finding. The proteins involved for this result are wide ranging, and information is
lacking to help directly address the mechanistic role of NAT1. To direct future
research efforts proteomic and acetylomic analysis of MDA-MB-231 parental and
NAT1 knockout clone cell lines are being conducted. The results of these studies
will guide future research into proteins that could be involved in the observed
differences in anchorage-independent colony formation. In addition, proteomics
and acetylomics will allow for greater understanding of NAT1’s role in cellular
biology.

The mammalian cell contains more than 8,000 unique acetylation sites on
proteins [162-164]. Protein acetylation occurs both co-translationally onto the
N terminal residue of a protein and post-translationally onto the Nε amino group
of lysine residues. Lysine acetylation is catalyzed by multiple families of lysine
acetyltransferases (KATs) and reversed by lysine deacetylases (KDACs). AcCoA
is an essential donor of acetyl groups for acetylation in eukaryotic cells. Reduced
AcCoA carboxylase (ACC1) expression decreases the amount of AcCoA that
moves through the fatty acid synthesis pathway, resulting in an increased cellular
level of AcCoA, globally increased histone acetylation, and altered transcriptional
regulation [165, 166]. Increased conversion of AcCoA into malonyl-CoA reduces
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the pool of cellular acetyl-CoA, and globally decreased histone acetylation [166].
Although acetylation correlates with the level of AcCoA, it is unclear whether
AcCoA is rate-limiting for the activity of all KATs. The results from chapter three,
four, and five show decreased NAT1 activity increases the concentration of
AcCoA within a cell. This control of AcCoA by NAT1 may mean that NAT1 can
control the level of protein and histone acetylation.

The growing amount of literature on the importance of protein acetylation
underscores the importance of understanding how NAT1 influences AcCoA
concentration, protein post translation modifications, and histone acetylation. The
use of mass spectrometry can be used to explore how NAT1 activity can affect
the protein post translation modification landscape, also known as acetylomics.
Also, NAT1 activity control of cellular AcCoA could provide interesting research in
spermatogenesis. During the formation of sperm, cells go through a period of
hyperacetylation. During the hyperacetylation stage, cells could repress NAT1
expression, so AcCoA levels increase. The NAT1 activity can be determined for
tissues from different stages of spermatogenesis. The possible repression of
NAT1 activity should align with the period of hyperacetylation. As discussed in
chapter four, overexpression NAT1 does not seem to affect the AcCoA
concentration compared to the parental cell line. The reason for this result is still
unclear, and could benefit from additional investigations.

As this chapter highlights, there are various experiments that can be
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pursued as an extension of work presented in this dissertation. The extended
research should reveal interesting roles for NAT1 in tumorigenesis, anchorageindependent colony formation, and cellular AcCoA concentrations. The future of
NAT1 research should prove to be of considerable interest as the massive voids
in understanding of NAT1’s endogenous role is further elucidated.
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ABBREVIATIONS
A

Adenine

ACC1

AcCoA carboxylase

AcCoA

Acetyl-Coenzyme A

ANOVA

Analysis of variance

Arg

Arginine

cDNA

Complementary deoxyribonucleic acid

CO2

Carbon dioxide

Cas9

CRISPR-associated 9 enzyme

CRISPR

Clustered Regularly Interspaced Palindromic Repeats

DHF

Dihydrofolate

DMBA

7,12-dimethylbenzanthracene

ER

Estrogen receptor

F344

Fischer 344 rat

G

Guanine

H&E

Hematoxylin and eosin

KATs

lysine acetyltransferases

KDACs

lysine deacetylases

kg

kilogram

mg

milligram

ml

milliliter
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MNU

Methyl-nitrosourea/N-methylnitrosourea/1-nitroso-1-methylurea

MTX

Methotrexate

N

Nitrogen

NAT1

Arylamine N-Acetyltransferase 1

NAT2

Arylamine N-Acetyltransferase 2

O

Oxygen

PABG

p-aminobenzoylglutamate

PAM

protospacer adjacent motif

PCR

Polymerase chain reaction

qPCR

Real-time quantitative polymerase chain reation

Phe

Phenylalanine

RNA

Ribonucleic acid

SEM

Standard error mean

shRNA

Short hairpin ribonucleic acid

T

Thymine

THF

Tetrahydrofolate

Tyr

Tyrosine

Val

Valine

WKY

Wistar Kyoto rat

°C

Degrees Celsius

µ

Micro
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